Clinical Obsessive-Compulsive Disorders in Adults and Children


Clinical Obsessive-Compulsive Disorders in Adults and Children

Clinical Obsessive-Compulsive Disorders in Adults and Children is a complete, comprehensive overview of OCD, covering its underlying causes, manifestations and treatment. The book begins by covering the basic science of OCD and its biological basis and mechanisms. It discusses the treatment for both adults and children with an emphasis on providing information for clinicians to use in their everyday practice. Using the latest information regarding evidence-based treatments, it takes the reader through medication options, including behavioural therapy, support groups and recent developments in surgical treatment. The clinical manifestations of OCD are covered, as well as the differentiation between OCD and other neuropsychiatric disorders with similar presentations. Chapters on spectrum illnesses including body dysmorphic disorder, impulse control disorders such as trichotillomania, and hoarding are also included. This book will appeal to all mental health professionals, from practitioners to researchers, working in the field of compulsive disorders.

Abel J (1993). Exposure with response prevention and serotonergic antidepressants in the treatment of obsessive compulsive disorder. Behav Res Ther 3: 463–478.
Abelson JF, Kwan KY, O'Roak BJ, et al. (2005). Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 310: 317–320.
Abelson JL, Curtis GC, Sagher O, et al. (2005). Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 57: 510–516.
Aboujaoude E, Barry JJ, Gamel N (2009). Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29: 51–55.
Abramowitz J, Franklin M, Schwartz S, Furr J (2003a). Symptom presentation and outcome of cognitive-behavior therapy for obsessive-compulsive disorder. J Consult Clin Psychol 71: 1049–1057.
Abramowitz J, Taylor S, McKay D (2005a). Potentials and limitations of cognitive treatments for obsessive-compulsive disorder. Cogn Behav Ther 34: 140–147.
Abramowitz JS (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review of the controlled treatment literature. J Consult Clin Psychol 65: 44–52.
Abramowitz JS (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 65: 44–52.
Abramowitz JS (2006). Understanding and Treating Obessive-Compulsive Disorder: A Cognitive-Behavioral Approach. Mahway NJ: Lawrence Erlbaum.
Abramowitz JS, Deacon B, Olatunji BO, et al. (2010a). Assessment of obsessive-compulsive symptoms: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess 22: 180–198.
Abramowitz JS, Foa EB (1998). Worries and obsessions in individuals with obsessive-compulsive disorder with and without comorbid generalized anxiety disorder. Behav Res Ther 36: 695–700.
Abramowitz JS, Foa EB (2000). Does comorbid major depressive disorder influence outcome of exposure and response prevention for OCD? Behav Ther 31: 795–800.
Abramowitz JS, Foa EB, Franklin ME (2003). Exposure and ritual prevention for obsessive-compulsive disorder: Effectiveness of intensive versus twice-weekly treatment sessions. J Consult Clin Psychol 71: 394–398.
Abramowitz JS, Foa EB, Franklin ME (2003). Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 71: 394–398.
Abramowitz JS, Franklin ME, Kozak MJ, Street GP, Foa EB (2000). The effects of pretreatment depression on cognitive-behavioral treatment outcome in OCD clinic patients. Behav Ther 31: 517–528.
Abramowitz JS, Franklin ME, Schwartz SA, Furr JM (2003). Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. J Consult Clin Psychol 71: 1049–1057.
Abramowitz JS, Franklin ME, Street G, Kozak M, Foa EB (2000). Effects of comorbid depression on response to treatment for obsessive-compulsive disorder. Behav Ther 31: 517–528.
Abramowitz JS, Meltzer-Brody S, Leserman J, et al. (2010b). Obsessional thoughts and compulsive behaviors in sample of women with postpartum mood symptoms. Arch Women Mental Health doi: 10.1007/s00737-010-0172-4.
Abramowitz JS, Schwartz SA, Moore KM (2003c). Obsessional thoughts in postpartum females and their partners: Content, severity and relationship with depression. J Clin Psychol in Medical Settings 10: 157–164.
Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR (2003). Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. Anxiety Disord 17: 461–478.
Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR (2003b). Obsessive-compulsive symptoms in pregnancy and the puerperium: A review of the literature. J Anxiety Disord 17: 461–478.
Abramowitz JS, Storch EA, Keely M, Cordell E (2007). Obsessive-compulsive disorder with comorbid major depression: What is the role of cognitive factors? Behav Res Ther 45: 2257–2267.
Abramowitz JS, Taylor S, McKay D (2009). Obsessive-compulsive disorder. Lancet 374: 491–499.
Abramowitz JS, Taylor S, McKay D (eds.) (2008). Clinical Handbook of Obsessive-Compulsive Disorder and Related Problems. Baltimore, MD: Johns Hopkins University Press.
Abramowitz JS, Wheaton MG, Storch EA (2008). The status of hoarding as a symptom of obsessive-compulsive disorder. Behav Res Ther 46: 1026–1033.
Abramowitz JS, Wheaton MG, Storch EA (2008). The status of hoarding as a symptom of obsessive-compulsive disorder. Behav Res Ther 46: 1026–1033.
Abramowitz JS, Whiteside SP, Deacon BJ (2005b). The effectiveness of treatment for pediatric obsessive-compulsive disorder: a meta-analysis. Behav Ther 36: 55–63.
Achenbach T, Edelbrock C (1991). Manual for the Child Behavior Checklist and Revised Child Behavior Profile. Burlington, VT: University of Vermont.
Ackerman DL, Greenland S (2002). Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 22: 309–317.
Ackerman DL, Greenland S, Bystritsky A (1999). Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 19: 459–465.
Adams GB, Waas GA, March JS, Smith MC (1994). Obsessive compulsive disorder in children and adolescents: the role of the school psychologist in identification, assessment, and treatment. Sch Psychol Q 9: 274–294.
Adams P (1973). Obsessive Children (p. 193). New York: Brummer/Mazel.
Albano A, March J, Piacentini J (1999). Cognitive behavioral treatment of obsessive-compulsive disorder. In Ammerman R, Hersen M, Last C (eds.) Handbook of Prescriptive Treatments for Children and Adolescents (pp. 193–215). Boston, MA: Allyn & Bacon.
Albert U, Aguglia E, Maina G, Bogetto F (2002). Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63: 1004–1009.
Albertini RS, Phillips KA (1999). 33 cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 38: 453–459.
Alevizos B, Lykouras L, Iannis Z, et al. (2002). Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol 22: 461–467.
Alexander, GE, Crutcher, MD, DeLong, MR (1990). Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Progr Brain Res 85: 119–146.
Alexander, GE, DeLong, MR, Strick, PL (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381.
Allen A, Hadley SJ, Kaplan A, et al. (2008). An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr 13: 138–144.
Allen AJ, Leonard HL, Swedo SE (1995). Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 34: 307–311.
Allsopp M, Verduyn C (1990). Adolescents with obsessive–compulsive disorder: a case note review of consecutive patients referred to a provincial regional adolescent psychiatry unit. J Adolesc 13: 157−169.
Alonso P, Menchón J, Mataix-Cols D, et al. (2004). Perceived parental rearing style in obsessive–compulsive disorder: relation to symptom dimensions. Psychiatry Res 127: 267−278.
American Academy of Child Adolescent Psychiatry (1998). Official action summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 37(Suppl 10): S27–45.
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn revised. Washington, DC: American Psychiatric Press.
American Psychiatric Association (2000). Diagnostic and Statistical Manual, 4th edn, revised. Washington, DC: American Psychiatric Press.
American Psychiatric Association (2007). Practice Guidelines for the treatment of Patients with Obsessive Compulsive Disorder. Washington, DC: American Psychiatric Press.
American Psychiatric Association (2007). Practice Guidelines for the Treatment of Patients with Obsessive Compulsive Disorder. Washington, DC: American Psychiatric Press.
Amir N, Freshman M, Foa E (2000). Family distress and involvement in relatives of obsessive-compulsive disorder patients. J Anxiety Disord 14: 209–217.
Amir N, Freshman MS, Foa EB (2000). Family accommodation and rejection in relatives of OCD patients. J Anxiety Disord 14: 209–217.
An SK, Mataix-Cols D, Lawrence NS, et al. (2008). To discard or not to discard: the neural basis of hoarding symptoms in obsessive-compulsive disorder. Mol Psychiatry 14: 318–331.
Anderson SW, Damasio H, Damasio AR (2005). A neural basis for collecting behaviour in humans. Brain 128: 201–212.
Andrade C (1998). Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry 59: 255–256.
Andrews G, Slade T, Issakidis C (2002). Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-being. Br J Psychiatry 181: 306–314.
Anon. (1937). Surgery used on the soul-sick; relief of obsessions is reported. New York Times, p. 1.
Antony MM, Downie F, Swinson RP (1998). Diagnostic issues and epidemiology and obsessive-compulsive disorder. In Swinson RP, Antony M, Rachman S, Richter M (eds.) Obsessive-Compulsive Disorder: Theory, Research, and Treatment (pp. 3–32). New York: Guilford Press.
Antony MM, Downie F, Swinson RP (1998). Diagnostic issues and epidemiology in obsessive-compulsive disorder. In Swinson RP Antony MM, Rachman S, Richter RA (eds.) Obsessive Compulsive Disorder: Theory, Research and Treatment (pp. 3–32). New York: Guilford Press.
Aouizerate B, Guehl D, Cuny E, et al. (2005). Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat 1: 231–243.
Aouizerate, B, Cuny E, Martin-Guehl C, et al. (2004). Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 101: 682–686.
Appelbaum PS, Robbins PC, Roth LH (1999). Dimensional approach to delusions: comparison across types and diagnoses. Am J Psychiatry 156: 1938–1943.
Arnold PD, Richter MA (2001). Is obsessive-compulsive disorder an autoimmune disease? Cmaj 165: 1353–1358.
Arnold PD, Rosenberg DR, Mundo E, et al. (2004). Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 174: 530–538.
Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63: 769–776.
Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63: 769–776.
Arya DK (1994). Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br Med J 165: 728–733.
Asbahr FR, Castillo AR, Ito LM, et al. (2005). Group cognitive–behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive–compulsive disorder. J Am Acad Child Adolesc Psychiatry 44: 1128–1136.
Ashton AK, Weinstein WL (2002). Cyproheptadine for drug-induced sweating. Am J Psychiatry 159: 874–875.
Atmaca M, Kuloglu M, Tezcan E, et al. (2002). Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17: 115–119.
Attiullah N, Eisen JL, Rassmussen SA (2000). Clinical features of obsessive-compulsive disorder. Psych Clin N Am 23: 469–491.
Ayd FJ (1995). Lexicon of Psychiatry, Neurology, and the Neurosciences. Baltimore, MD: Williams & Wilkins.
Azrin NH, Nunn RG (1973). Habit reversal: a method of eliminating nervous habits and tics. Behav Res Ther 11: 619–628.
Azrin NH, Nunn RG, Frantz SE (1980). Treatment of hair pulling (trichotillomania): a comparative study of habit reversal and negative practice training. Behav Ther Exp Psychiatry 11: 13–20.
Baer L, Jenike MA (1992). Personality disorders in obsessive-compulsive disorder. Psychiatr Clin N Am 15: 803–812.
Baer L, Jenike MA, Ricciardi JN II, et al. (1990). Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch Gen Psychiatry 47: 826–830.
Baer L, Minichiello WW (1990). Behavior therapy for obsessive compulsive disorder. In Jenike MA, Baer L, Minichiello WE (eds.) Obsessive Compulsive Disorders: Theory and Management (pp. 203–232). Chicago, IL: Year Book Medical.
Bagley A, Abramowitz C, Kosson D (2009). Vocal affect recognition and psychopathy: converging findings across traditional and cluster analytic approaches to assessing the construct. J Abnorm Psychol 118: 388–398.
Bailey V (2001). Cognitive–behavioural therapies for children and adolescents. Adv Psychiatr Treat 7: 224–232.
Ballantine HTJr., Bouckoms AJ, Thomas EK, Giriunas IE (1987). Treatment of psychiatric illness by stereotactic cingulotomy. Biol Psychiatry 22: 807–819.
Ballenger JC (1999). Current treatments of the anxiety disorders in adults. Biol Psychiatry 46: 1579–1594.
Barrett P, Healy-Farrell L, March J (2004). Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry 43: 46–62.
Barrett PM (2007). FOCUS: Freedom from Obsessions and Compulsions Using Skills (Therapist Manual and Workbooks). Brisbane: Pathways Health and Research Centre.
Barrett PM, Farrell LJ, Dadds M, Boulter N (2005). Cognitive–behavioral family treatment of childhood obsessive–compulsive disorder: long-term follow-up and predictors of outcome. J Am Acad Child Adolesc Psychiatry 44: 1005–1014.
Barrett PM, Healy-Farrell L, March JS (2004). Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry 43: 46–62.
Barrett PM, Rasmussen P, Healy LJ (2001). The effects of obsessive–compulsive disorder on sibling relationships in late childhood and early adolescence: Preliminary findings. Aust Educ Dev Psychol 17: 82−102.
Barrett PM, Shortt A, Healy L (2002). Do parent and child behaviours differentiate families whose children have obsessive-compulsive disorder from other clinic and non-clinic families? J Child Psychol Psychiatry 43: 597–607.
Bartha R, Stein MB, Williamson PC, et al. (1998). A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry 155: 1584–1591.
Bartz JA, Hollander E (2006). Is obsessive-compulsive disorder an anxiety disorder? Prog Neuropsychopharmacol Biol Psychiatry 30: 338–352.
Basoglu M, Lax. T, Kasvikis Y, Marks I (1988). Predictors of improvement in obsessive-compulsive disorder. J Anxiety Disord 2: 299–317.
Baum M (1965). An automated apparatus for the avoidance training of rats. Psychol Rep 16: 1205–1211.
Baum M (1969a). Extinction of an avoidance response following a period of response prevention in the avoidance apparatus. Psychol Rep 18: 59–64.
Baum M (1969b). Paradoxical effect of alcohol on the resistance to extinction of an avoidance response in rats. J Compr Physiol Psychol 69: 238–240.
Baum M (1970). Effect of alcohol on the acquisition and resistance to extinction of avoidance responses in rats. Psychol Rep 26: 759–765.
Baxter L, Jr., Schwartz J, Bergman KS, et al. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 49: 681–689.
Baxter L, Schwartz J, Mazziotta J, et al. (1988). Cerebral glucose metabolic rates in nondepressed patients with obsessive compulsive disorder. Am J Psychiatry 145: 1560–1563.
Baxter LR (2001): Functional imaging of brain systems mediating obsessive-compulsive disorder. In Charney DS, Nestler EJ, Bunney BS (eds.) Neurobiology of Mental Illness (pp. 534–547). Oxford: Oxford University Press.
Baxter LR, Jr., Saxena S, Brody AL, et al. (1996). Brain mediation of obsessive-compulsive disorder symptoms: evidence from functional brain imaging studies in the human and nonhuman primate. Semin Clin Neuropsychiatry 1: 32–47.
Baxter LR, Schwartz JM, Bergmann KS, et al. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive compulsive disorder. Arch Gen Psychiatry 49: 681–689.
Baylé FJ, Krebs MO, Epelbaum C, Levy D, Hardy P (2001). Clinical features of panic attacks in schizophrenia. Eur Psychiatry 16: 349–353.
Bechara A, Damasio AR, Damasio H, Anderson SW (1994). Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50: 7–15.
Bechara A, Damasio H, Tranel D, Damasio AR (1997). Deciding advantageously before knowing the advantageous strategy. Science 275: 1293–1295.
Bejerot S, von Knorring L, Ekselius L (2000). Personality traits and smoking in patients with obsessive-compulsive disorder. Eur Psychiatry 15: 395–401.
Bellodi L, Scioto G, Diaferia G, Ronchi P, Smiraldi E (1992). Psychiatric disorders in families of patients with obsessive-compulsive disorder. Psychiatry Res 42: 111–120.
Benazon NR, Ager J, Rosenberg DR (2002). Cognitive behavior therapy in treatment-naive children and adolescents with obsessive-compulsive disorder: an open trial. Behav Res Ther 40: 529–39.
Benkelfat C, Nordahl TE, Semple WE, et al. (1990). Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Arch Gen Psychiatry 47: 840–848.
Berg CZ, Whitaker A, Davies M, Flament MF, Rapoport JL (1988). The survey form of the Leyton Obsessional Inventory-Child Version: norms from an epidemiological study. J Am Acad Child Adolesc Psychiatry 27: 759–763.
Bergeron R, Ravindran AV, Chaput Y, et al. (2002). Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 22: 148–154.
Berle D, Phillips ES (2006). Disgust and obsessive-compulsive disorder: an update. Psychiatry 69: 288–238.
Berman I, Kalinowski A, Berman S, Lengua J, Green AI (1995). Obsessive-compulsive symptoms in chronic schizophrenia. Compr Psychiatry 36: 6–10.
Bermanzohn PC, Porto L, Arlow PB, et al. (1997). Are some neuroleptic-refractory symptoms of schizophrenia really obsessions? CNS Spectr 2: 51–57.
Bermanzohn PC, Porto L, Arlow PB, et al. (2000). Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophr Bull 26: 517–525.
Berney A, D. Sookman, Leyton SN, et al. (2006). Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry 59: 853–857.
Besiroglu L, Uguz F, Ozbebit O, et al. (2006). Longitudinal assessment of subtype categories in obsessive-compulsive disorder. Depress Anxiety 113: 440–446.
Bienvenu O, Samuels J, Riddle M, et al. (2000). The relationship of obsessive-compulsive disorder to possible spectrum disorders: Results from a family study. Biol Psychiatry 48: 287–293.
Bienvenu OJ, Samuels JF, Riddle MA, et al. (2000). The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry 48: 287–293.
Binder DK, Iskandar BJ (2000). Modern neurosurgery for psychiatric disorders. Neurosurgery 47: 9–21; discussion 21–23.
Bingley T, Leksell L, Meyerson BA, Rylander G (1977). Long term results of stereotactic capsulotomy in chronic obsessive-compulsive neurosis. In Sweet WH, Obrador Alcalde S, Martín-Rodríguez JG (eds.) Proceedings of the Fourth World Congress of Psychiatric Surgery, September, Neurosurgical Treatment in Psychiatry, Pain, and Epilepsy Madrid, 1975 (pp.287–299). Baltimore, MD: University Park Press.
Black DW, Blum NS (1992). Obsessive-compulsive disorder support groups: the Iowa model. Compr Psychiatry 33: 65–71.
Black DW, Blum NS (1992). Obsessive-compulsive disorder support groups: the Iowa model. Compr Psychiatry 33: 65–71.
Black DW, Monahan P, Gable J, et al. (1998). Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 59: 420–425.
Black DW, Noyes R, Jr, Pfohl B, Goldstein RB, Blum N (1993). Personality disorder in obsessive-compulsive volunteers, well comparison subjects, and their first-degree relatives. Am J Psychiatry 150: 1226–1232.
Blair M, Stewart-Brown S, Waterston T, Crowther R (2003). Child Public Health. New York: Oxford University Press.
Blanco C, Olfson M, Stein DJ, et al. (2006). Treatment of obsessive-compulsive disorder by US psychiatrists. J Clin Psychiatry 67: 946–951.
Bland RC, Newman SC, Orn H (1987). Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand 75: 383–391.
Bloch MH, Landeros-Weisenberger A, Dombrowski P, et al. (2007). Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 62: 839–846.
Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622–632.
Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622–632.
Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622–632.
Bloch MH, Landeros-Weisenberger A, Kelmendi BK, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622–632.
Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF (2008). Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 165: 1532–1542.
Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF (2008a). Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 165: 1532–1542.
Bloch MH, Landeros-Weisenberger A, Sen S, et al. (2008b).Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet 147B: 850–858.
Boersma K, den Hengst S, Dekker J, Emmelkamp PMG (1976). Exposure and response prevention in the natural environment: A comparison with obsessive-compulsive patients. Behav Res Ther 14: 19–24.
Bogetto F, Albert U, Maina G (2002). Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 12: 181–186.
Bogetto F, Bellino S, Vaschetto P, Ziero S (2000). Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96: 91–98.
Bohne A, Savage CR, Deckersbach T, Keuthen NJ, Wilhelm S (2008). Motor inhibition in trichotillomania and obsessive-compulsive disorder. J Psychiatry Res 42: 141–150.
Bolton D, Collins S, Steinberg D (1983). The treatment of obsessive–compulsive disorder in adolescence: a report of 15 cases. Br J Psychiatry 142: 456−464.
Bolton D, Collins S, Steinberg D (1983). Treatment of obsessive-compulsive disorder in adolescence: a report of fifteen cases. Br J Psychiatry 142: 456–464.
Bolton D, Luckie M, Steinberg D (1995). Long-term course of obsessive-compulsive disorder treated in adolescence. J Am Acad Child Adolesc Psychiatry 34: 1441–1450.
Bolton D, Luckie M, Steinberg D (1995). Obsessive compulsive disorder treated in adolescence: 14 long term case histories. Clin Child Psychol Psychiatry 1: 409–430.
Bolton D, Perrin S (2008). Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry 39: 11–22.
Boschen MJ, Drummond LM, Pillay A (2008). Treatment of severe, treatment refractory obsessive-compulsive disorder: a study of inpatient and community treatment. CNS Spectr 13: 1056–1085.
Bottas A, Cooke RG, Richter MA (2005). Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci 30: 187–193.
Boucard C, Rheaume J, Ladouceur R (1999). Responsibility and perfectionism in OCD: an experimental study. Behav Res Ther 37: 293–248.
Boulougouris JC, Bassiakos L (1973). Prolonged flooding in cases with obsessive-compulsive neurosis. Behav Res Ther 11: 227–231.
Boyer EW, Shannon M (2005). The serotonin syndrome. N Engl J Med 352: 1112–1120.
Brakoulias V, Starcevic V (2008). Symptom subtypes of obsessive compulsive disorder: Are they relevant for treatment? Aust N Z J Psychiatry 42: 651–661.
Brawman-Mintzer O, Lydiard RB, Phillips KA, et al. (1995). Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry 152: 1665–1667.
Breiter HC, Filipek PA, Kennedy DN, et al. (1994). Retrocallosal white matter abnormalities in patients with obsessive-compulsive disorder. Arch Gen Psychiatry 51: 663–664.
Breiter HC, Rauch SL, Kwong KK, et al. (1996). Functional magnetic resonance imaging of symptom provocation in obsessive compulsive disorder. Arch Gen Psychiatry 53: 595–606.
Bressi C, Guggeri G (1996). Obsessive-compulsive disorder and the family emotional environment. New Trend Exp Clin Psychol 12: 265–269.
Bridge JA, Iyengar S, Salary CB, et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297: 1683–1696.
Bridges PK, Bartlett JR, Hale AS, et al. (1994). Psychosurgery: stereotactic subcaudate tractomy. An indispensable treatment. Br J Psychiatry 165: 599–611; discussion 612–593.
Brody AL (1996). Acute dystonia induced by rapid increase in risperidone dosage. J Clin Psychopharmacol 16: 461–462.
Brody AL, Saxena S, Schwartz JM, et al. (1998). FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive-compulsive disorder. Psychiatry Res 84: 1–6.
Brown ES (1997). Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 42: 325–326.
Buchanan AW, Meng KS, Marks IM (1996). What predicts improvement and compliance during the behavioral treatment of obsessive compulsive disorder? Anxiety 2: 22–27.
Buhlmann U, McNally RJ, Etcoff NL, et al. (2004). Emotion recognition deficits in body dysmorphic disorder. J Psychiatr Res 38: 201–206.
Buhlmann U, Wilhelm S, McNally RJ, et al. (2002). Interpretive biases for ambiguous information in body dysmorphic disorder. CNS Spectr 7: 435–443.
Burland J (1995). Journey of hope: a family-to-family self help education program. Self Help 6: 20–22.
Byerly M, Goodman W, Acholonu W, Bugno R, Rush AJ (2005). Obsessive-compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res 76: 309–316.
Bymaster FP (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87–96.
Bystritsky A Ackerman DL, Rosen RM, et al. (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65: 565–568.
Bystritsky A, Munford PR, Rosen RM, et al. (1996). A preliminary study of partial hospital management of severe obsessive-compulsive disorder. Psychiatr Serv 47: 170–174.
Calamari JE, Wiegartz PS, Janeck AS (1999). Obsessive compulsive disorder subgroups: a symptom-based clustering approach. Behav Res Ther 37: 113–125.
Calamari JE, Wiegartz PS, Riemann BC, et al. (2004). Obsessive-compulsive disorder subtypes: an attempted replication and extension of a symptom-based taxonomy. Behav Res Ther 42: 647–670.
Calvocoressi L, Lewis B, Harris M, et al. (1995). Family accommodation in obsessive compulsive disorder. Am J Psychiatry 152: 441–443.
Calvocoressi L, Lewis B, Harris M, et al. (1995). Family accommodation in obsessive-compulsive disorder. Am J Psychiatry 152: 441–443.
Cameron CL (2007). Obsessive-compulsive disorder in children and adolescents. J Psychiatr Ment Health Nurs 14: 696–704.
Cameron LD, Leventhal H (eds.) (2003).The Self-regulation of Health and Illness Behavior. London: Routledge.
Cannistraro PA, Makris N, Howard JD, et al. (2007). A diffusion tensor imaging study of white matter in obsessive-compulsive disorder. Depress Anxiety 24: 440–446.
Capps L, Sigman M, Sena R, Henker B, Whalen C (1996). Fear, anxiety and perceived control in children of agoraphobic parents. J Child Psychol Psychiatry 37: 445–452.
Carey P, Seedat S, Warwick J, et al. (2004). SPECT imaging of body dysmorphic disorder. J Neuropsychiat Clin Neurosci 16: 357–335.
Carey PD, Vythilingum B, Seedat S, et al. (2005). Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5: 44.
Carrion VG (1995). Naltrexone for the treatment of trichotillomania: a case report. J Clin Psychopharmacol 15: 444–445.
Carter CS, Braver TS, Barch DM, et al. (1998). Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 280: 747–749.
Cassano GB, Pini S, Saettoni M, Rucci P, Dell'Osso L (1998). Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry 59: 60–68.
Castle D, Phillips KA (2006). The OCD spectrum of disorders: a defensible construct?. Aust N Z J Psychiatry 40: 114–120.
Castle DJ, Phillips KA (2006). Obsessive-compulsive spectrum of disorders: a defensible construct? Aust N Z J Psychiatry 40: 114–120.
Catapano F, Sperandeo R, Perris F, Lanzaro M, Maj M (2001). Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 34: 62–68.
Cath DC, Spinhoven PH, Hoogduin CAL, et al. (2001). Repetitive behaviors in Tourette's syndrome and obsessive-compulsive disorder with and without tics: What are the differences? Psychiatry Res 101: 171–185.
Cath DC, Spinhoven PH, van der Wetering BJM, et al. (2000). The relationship between types and severity of repetitive behaviors in Gilles de la Tourette's syndrome and obsessive-compulsive disorder. J Clin Psychiatry 61: 505–513.
Catts S, McConaghy N (1975). Ritual prevention in the treatment of obsessive compulsive neurosis. Aust N Z J Psychiatry 9: 37–41.
Cavedo LC, Parker G (1994). Parental bonding instrument: exploring links between scores and obsessionality. Social Psychiatry Psychiatr Epidemiol 29: 78−82.
Cermele JA, Melendez-Pallitto L, Pandina GJ (2001). Intervention in compulsive hoarding. A case study. Behav Modif 25: 214–232.
Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735–1740.
Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735–1740.
Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735–1740.
Chakrabarty K, Bhattacharyya S, Khanna S, Christopher R (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735–1740.
Chamberlain SR, Fineberg NA, Blackwell AD, et al. (2007). A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 45: 654–662.
Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ (2006). Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry 163: 1282–1284.
Chamberlin J (1978). On Our Own: Patient-controlled Alternatives to the Mental Health System. Toronto: McGraw-Hill.
Chambless DL, Steketee G (1999). Expressed emotion and behavior therapy outcome: a prospective study with obsessive- compulsive and agoraphobic outpatients. J Consult Clin Psychol 67: 658–665.
Charash M, McKay D (2002). Attention bias for disgust. J Anxiety Disord 16: 529–541.
Chen EY, Matthews L, Allen C, Kuo JR, Linehan MM (2008). Dialectical behavior therapy for clients with binge-eating disorder or bulimia nervosa and borderline personality disorder. Int J Eating Disord 41: 505–512.
Cho DY, Lee WY, Chen CC (2008). Limbic leukotomy for intractable major affective disorders: a 7-year follow-up study using nine comprehensive psychiatric test evaluations. J Clin Neurosci 15: 138–142.
Chorpita BF, Barlow DH (1998). The development of anxiety: the role of control in the early environment. Psychol Bull 124: 3–21.
Christensen DD, Greist JH (2001). The challenge of obsessive-compulsive disorder hoarding. Primary Psychiatry 8: 79–86.
Christenson G, Pyle R, Mitchell J (1991). Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 52: 415–417.
Christenson GA, Mackenzie TB, Mitchell JE, Callies AL (1991b). A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 148: 1566–1571.
Christenson GA, Pyle RL, Mitchell JE (1991a). Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 52: 415–417.
Cisler JM, Reardon JM, Williams NL, Lohr JM (2007). Anxiety sensitivity and disgust sensitivity interact to predict contamination fears. Pers Individ Dif 42: 935–946.
Clayton AH, Pradko JF, Croft HA, et al. (2002). Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357–366.
Clayton AH, Warnock JK, Kornstein SG, et al. (2004). A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 65: 62–67.
Clomipramine Collaborative Study Group. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730–738.
Coglan R, Lawrence D, Jablensky A (2001). Duty to Care: Physical Illness in People with Mental Illness. Perth: University of Western Australia.
Cohen LR, Hollander E (1997). Obsessive-compulsive spectrum disorders. In Hollander E, Stein DJ (ed.) Obsessive-Compulsive Disorders (pp. 47–74). New York: Marcel Dekker.
Cole JD, Kazarian SS (1988). The Level of Expressed Emotion Scale: a new measure of expressed emotion. J Clin Psychol 44: 392–397.
Coles ME, Frost RO, Heimberg RG, Steketee G (2003). Hoarding behaviors in a large college sample. Behav Res Ther 41: 179–194.
Coles ME, Pinto A, Mancebo MC, Rasmussen SA, Eisen JL (2008). OCD with comorbid OCPD: a subtype of OCD? J Psychiatry Res 42: 289–296.
Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005). The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66: 49–51.
Conroy M, Menard W, Fleming-Ives K, et al. (2008). Prevalence and clinical characteristics of body dysmorphic disorder in an adult inpatient setting. Gen Hosp Psychiatry 30: 67–72.
Cooper M (1993). A group for families of obsessive-compulsive persons. Fam Soc 77: 301–307.
Cooper M (1996). Obsessive-compulsive disorder: effects on family members. Am J Orthopsychiatry 66: 296–304.
Coric V, Milanovic S, Wasylink S, et al. (2003). Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 167: 219–220.
Coric V, Taskiran S, Pittenger C, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 1 58: 424–428.
Coric V, Taskiran S, Pittenger C, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58: 424–428.
Coric V, Taskiran S, Pittenger C, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58: 424–428.
Coric V, Taskiran S, Pittenger C, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58: 424–428.
Cosgrove GR (2000). Surgery for psychiatric disorders. CNS Spectr 5: 43–52.
Cosoff SJ, Hafner RJ (1998). The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust N Z J Psychiatry 32: 67–72.
Cotterill JA (1996). Body dysmorphic disorder. Dermatol Clin 14: 457–463.
Cotterill JA, Cunliffe WJ (1997). Suicide in dermatological patients. Br J Dermatol 137: 246–250.
Cottraux J, Bouvard MA, Milliery M (2005). Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 34: 185–192.
Cox BJ, Swinson RP, Morrison B, Lee PS (1993). Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry 24: 149–153.
Craig T, Hwang MY, Bromet EJ (2002). Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry 159: 592–598.
Craighead W, Evans D, Robins C (1992). Unipolar depression. In Turner SM, Calhoun KS, Adams H, (eds.) Handbook of Clinical Behavior Therapy, 2nd edn (pp. 99–116). New York: Wiley.
Crerand CE, Phillips KA, Menard W, et al. (2005). Nonpsychiatric medical treatment of body dysmorphic disorder. Psychosomatics 46: 549–555.
Crino R, Andrews G (1996). Obsessive-compulsive disorder and axis I comorbidity. J Anxiety Disord 19: 37–46.
Crino RD, Andrews G (1996). Personality disorder in obsessive-compulsive disorder: a controlled study. J Psychiat Res 30: 29–38.
Crisp AH, Gelder MG, Rix S, Meltzer HI, Rowlands OJ (2000). Stigmatisation of people with mental illness. Br J Psychiatry 177: 4–7.
Cromer KR, Schmidt NB, Murphy DL (2007).Do traumatic events influence the clinical expression of compulsive hoarding? Behav Res Ther 45: 2581–2592.
Cunill R, Castells X, Simeon D (2009). Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry 70: 70–82.
D'Amico G, Cedro C, Muscatello MR, et al. (2003). Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 27: 619–623.
da Rocha FF, Correa H, (2007). Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 1550–1551.
Dalrymple KL, Herbert JD (2007). Acceptance and commitment therapy for generalized social anxiety disorder: A pilot study. Behav Modif 31: 543–568.
Davidson L (2003). Living Outside Mental Illness: Qualitative Studies of Recovery in Schizophrenia. New York: New York University Press.
De Berardis D,Campanella D, Gambi F, et al. (2005). Insight and alexithymia in adult outpatients with obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 255: 350–358.
de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D (2002). Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry 63: 104–107.
de Haan L, Hoogeboom B, Beuk N, et al. (2006). Reliability and validity of the Yale–Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull 39: 25–30.
de Haan L, Hoogenboom B, Beuk N, van Amelsvoort T, Linszen D (2005). Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can J Psychiatry 50: 519–24.
de Mathis MA, Diniz JB, do Rosario MC, et al. (2006). What is the optimal way to subdivide obsessive-compulsive disorder? CNS Spectr 11: 762–768, 771–774, 776–779.
De Sousa A (2008). An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol 18: 30–33.
Deacon B, Olatunji BO (2007). Specificity of disgust sensitivity in the prediction of behavioral avoidance in contamination fear. Behav Res Ther 45: 2110–2120.
Debattista C, Solvason B, Poirier J, Kendrick E, Loraas E (2005). A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 66: 844–848.
Deckersbach T, Savage CR, Phillips KA, et al. (2000). Characteristics of memory dysfunction in body dysmorphic disorder. J Int Neuropsychol Soc 6: 673–681.
Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS (1990). Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 157: 762–765.
Demal U, Lenz G, Mayrhofer A, Zapotoczky, H-G, Zitterl W (1993). Obsessive-compulsive disorder and depression. A retrospective study on course and interaction. Psychopathology 26: 145–150.
Denys D (2006). Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin N Am 29: 553–584, xi.
Denys D, de Geus F, van Megen HJ, Westenberg HG (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65: 1040–1048.
Denys D, van der Wee N, van Megen HJ, Westenberg HG (2003). A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23: 568–575.
Denys D, van Megen H, Westenberg H (2002). Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 63: 700–703.
Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004). A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65: 37–43.
DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S (1990). Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 26: 54–59.
DeVeaugh-Geiss J, Landau P, Katz R (1989). Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 25: 36–40.
Devinsky O, Morrell MJ, Vogt BA (1995). Contributions of anterior cingulate cortex to behaviour. Brain 118: 279–306.
Devulapalli KK, Welge JA, Nasrallah HA (2008). Temporal sequence of clinical manifestation in schizophrenia with co-morbid OCD: review and meta-analysis. Psychiatry Res 161: 105–108.
Dhillon S, Scott LJ, Plosker GL (2006). Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 20: 763–790.
Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. (2006). Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63: 778–785.
Didie ER, Menard W, Stern AP, Phillips KA (2008). Occupational functioning and impairment in adults with body dysmorphic disorder. Compr Psychiatry 49: 561–569.
Didie ER, Walters MM, Pinto A, et al. (2007). Comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder versus body dysmorphic disorder. Ann Clin Psychiatry 19: 181–186.
Dimeff L, Rizvi SL, Brown M, Linehan MM (2000). Dialectical behavior therapy for substance abuse: A pilot application to methamphetamine dependent women with borderline personality disorder. Cogn Behav Pract 7: 457–468.
Diniz JB, Rosario-Campos MC, Shavitt RG, et al. (2004). Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. J Clin Psychiatry 65: 22–27.
Dinn WM, Harris CL, Aycicegi A, Greene P, Andover MS (2002). Positive and negative schizotypy in a student sample: neurocognitive and clinical correlates. Schizophr Res 56: 171–185.
Dixon L, Lucksted A, Stewart B, et al. (2004). Outcomes of peer-taught 12-week family-to-family education program for severe mental illness. Acta Psychiatr Scand 109: 207–215.
do Rosario-Campos MC, Leckman JF, Curi M, et al. (2005). A family study of early-onset obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 136B: 92–97.
Dollard J, Miller E (1950). Personality and Psychotherapy: An Analysis in Terms of Learning, Thinking and Culture. New York: McGraw-Hill.
Dominguez RA, Backman KE, Lugo SC (1999). Demographics, prevalence, and clinical features of the schizo-obsessive subtype of schizophrenia. CNS Spectr 4: 50–56.
Dougherty DD, Baer L, Cosgrove GR, et al. (2002). Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 159: 269–275.
Dougherty DD, Loh R, Jenike MA, Keuthen NJ (2006). Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry 67: 1086–1092.
Drummond LM (1993). The treatment of severe, chronic, resistant obsessive-compulsive disorder. an evaluation of an in-patient programme using behavioral psychotherapy in combination with other treatments. Br J Psychiatry 163: 223–229.
Drummond LM, Pillay A, Kolb P, Rani S (2007). Specialised in-patient treatment for severe, chronic, resistant obsessive-compulsive disorder. Psychiatr Bull 31: 49–52.
du Boisgueheneuc F, Levy R, Volle E, et al. (2006). Functions of the left superior frontal gyrus in humans: a lesion study. Brain 129: 3315–3328.
DuPont RL, Rice DP, Shiraki S, Rowland CR (1995).Economic costs of obsessive-compulsive disorder. Med Interface 8: 102–109.
Ebert D, Speck O, Konig A, et al. (1997). 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res 74: 173 –176.
Ecker W, Gonner S (2008). Incompleteness and harm avoidance in OCD symptom dimensions. Behav Res Ther 46: 895–904.
Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24: 1011–1030.
Eifert G, Heffner M (2003). The effects of acceptance versus control contexts on avoidance of panic-related symptoms. J Behav Ther Exp Psychiatry 34: 293–312.
Eisen J, Phillips K, Baer L, et al. (1998). The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 155: 102–108.
Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA (1997). Obsessive-compulsive disorder in patients with schizophrenia and schizoaffective disorder. Am J Psychiatry 154: 271–273.
Eisen JL, Goodman WK, Keller MB, et al. (1999). Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry 60: 346–351.
Eisen JL, Goodman WK, Keller MB, et al. (1999). Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 60: 346–351.
Eisen JL, Phillips KA, Baer L, et al. (1998). The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 155: 102–108.
Eisen JL, Phillips KA, Coles ME, et al. (2004). Insight in obsessive compulsive disorder and body dysmorphic disorder. Compr Psychiatry 45: 10–15.
Eisen JL, Phillips KA, Rasmussen SA, et al. (1998). The Brown Assessment of Beliefs Scale (BABS): reliability and validity. Am J Psychiatry 155: 102–8.
Eisen JL, Rasmussen SA (1993). Obsessive-compulsive disorder with psychotic features. J Clin Psychiatry 54: 373–379.
Eisen JL, Rasmussen SA, Phillips KA, et al. (2001). Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 42: 494–497.
El-Hai J (2005). The Lobotomist: A Maverick Medical Genius and his Tragic Quest to Rid the World of Mental Illness. Hoboken, NJ: Wiley.
Elkin I, Shea M, Watkins, IS, et al. (1989). National Institute of Mental Health Treatment of Depression Collaborative Research program: General effectiveness of treatments. Arch Gen Psychiatry 46: 971–982.
Emmelkamp PME, Beens H (1991). Cognitive therapy with obsessive compulsive disorder: a comparative evaluation. Behav Res Ther 29: 293–300.
Emmelkamp PME, Visser S, Hoekstra R (1988). Cognitive therapy versus exposure in vivo in the treatment of obsessive compulsives. Cogn Ther Res 12: 103–114.
Emsley RA, Roberts MC, Rataemane S, et al. (2002). Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 63: 9–14.
Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ (1999). Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. J Child Adolesc Psychopharmacol 9: 43–49.
Epston, D, White M (1990). Narrative Means to Therapeutic Ends. New York: Norton.
Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM (2005). Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 59: 219–22.
Erzegovesi S, Cavallini MC, Cavedini P, et al. (2001). Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21: 488–492.
Erzegovesi S, Cavallini MC, Cavedini P, et al. (2001). Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21: 488–492.
Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005). Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15: 69–74.
Eslinger PJ, Damasio AR (1985). Severe disturbance of higher cognition after bilateral frontal lobe ablation: Patient EVR. Neurology 35: 1731–1741.
Evaluation of Genomic Applications in Practice and Prevention Working Group (2007). Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 9: 819–825.
Eysenbach G (2003). The impact of the Internet on cancer outcomes. CA Cancer J Clin 53: 356–371.
Fabisch K, Fabisch H, Langs G, Huber HP, Zapotoczky HG (2001). Incidence of obsessive-compulsive phenomena in the course of acute schizophrenia and schizoaffective disorder. Eur Psychiatry 16: 336–341.
Fallon BA, Javitch JA, Hollander E, Liebowitz MR (1992). Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. J Clin Psychiatry 52: 457–460.
Fallon BA, Liebowitz MR, Campeas R, et al. (1998). Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 55: 918–924.
Faragian S, Kurs R, Poyurovsky M (2008). Insight into obsessive-compulsive symptoms and awareness of illness in adolescent schizophrenia patients with and without OCD. Child Psychiatry Hum Dev 39: 39–48.
Faravelli C, Salvatori S, Galassi F, et al. (1997). Epidemiology of somatoform disorders: a community survey in Florence. Soc Psychiatry Psychiatr Epidemiol 32: 24–29.
Feder R (1995). Clonidine treatment of excessive sweating. J Clin Psychiatry 56: 35.
Feldman MD (2000). Munchausen by Internet: detecting factitious illness and crisis on the Internet. South J Med 93: 669–672.
Feldman RP, Alterman RL, Goodrich JT (2001). Contemporary psychosurgery and a look to the future. J Neurosurg 95: 944–956.
Fenton WS, McGlashan TH (1986). The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143: 437–441.
Ferguson JM (2001). SSRI antidepressant medications: adverse effects and tolerability. J Clin Psychiatry 3: 22–27.
Figee M, Denys D (2009). New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr 14(Suppl 3): 13–23.
Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS (1998). Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 8: 61–67.
Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8: 107–129.
Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ (2007b). Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol 22: 313–322.
Fineberg NA, Sharma P, Sivakumaran T, Sahakian B, Chamberlain S (2007). Does obsessive-compulsive personality disorder belong within the obsessive-compulsive spectrum? CNS Spectr 12: 467–482.
Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20: 223–226.
Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007a). Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17: 430–439.
Finkel S, Costa E, Silva J, et al. (1997). Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int J Geriatr Psychiatry 12: 1060–1061.
Fins JJ (2003). From psychosurgery to neuromodulation and palliation: history's lessons for the ethical conduct and regulation of neuropsychiatric research. Neurosurg Clin N Am 14: 303–319, ix–x.
Fireman B, Koran L, Leventhal J, Jacobson A (2001). The prevalence of clinically recognized obsessive-compulsive disorder in a large health maintenance organization. Am J Psychiatry 158: 1904–1910.
Fireman B, Koran LM, Leventhal JL, Jacobson A (2001). The prevalence of clinically recognized obsessive-compulsive disorder in a large health maintenance organization. Am J Psychiatry 158: 1904–1910.
Fischer DJ, Himle JA, Hanna GL (1998). Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes. Res Social Work Pract 8: 629–636.
Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR (1999). Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9: 115–123.
Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR (1999). Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9: 115–123.
Fitzgerald KD, Welsh RC, Gehring WJ, et al. (2005). Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder. Biol Psychiatry 1 57: 287–294.
Flaisher-Grinberg S, Klavir O, Joel D (2008). The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. Int J Neuropsychopharmacol 14: 1–15.
Flament MF, Rapoport JL, Berg CJ, et al. (1985a). Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42: 977–983.
Flament MF, Rapoport JL, Kilts C (1985b). A controlled trial of clomipramine in childhood obsessive compulsive disorder. Psychopharmacol Bull 21: 150–152.
Flament MF, Whitaker A, Rapoport JL, et al. (1988). Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27: 764–771.
Flessner CA, Conelea CA, Woods DW (2008). Styles of pulling in trichotillomania: exploring differences in symptom severity, phenomenology, and functional impact. Behav Res Ther 46: 345–357.
Flessner CA, Woods DW, Franklin ME, et al. (2007). The Milwaukee Inventory for Styles of Trichotillomania-Child Version (MIST-C): initial development and psychometric properties. Behav Modif 31: 896–918.
Foa E, Franklin M, Kozak M (1998). Psychosocial treatment for obsessive compulsive disorder: literature review. In Swinson RP Antony MM, Rachman S, Richter RA (eds.) Obsessive Compulsive Disorder: Theory, Research, and Treatment (pp. 258–276). New York: Guilford Press.
Foa E, Goldstein A (1978). Continuous exposure and complete response prevention in the treatment of obsessive compulsive neurosis. Behav Ther 9: 821–829.
Foa E, Kozak M (1985). Treatment of anxiety disorders: implications for psychopathology. In Tuma AH, Maser J (eds.) Anxiety and the Anxiety Disorders (pp. 421–461). Hillsdale, NJ: Erlbaum.
Foa EB (1979). Failure in treating obsessive-compulsives. Behav Res Ther 17: 169–176.
Foa EB Liebowitz MR, Kozak J, et al. (2005). Randomized placebo-controlled trial of ERP, clomipramine, and their combination in the treatment of OCD Am J Psychiatry 162: 151–161.
Foa EB, Grayson JB, Steketee GS, et al. (1983). Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol 51: 287–297.
Foa EB, Grayson JB, Steketee GS, et al. (1983). Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol 51: 287–297.
Foa EB, Huppert JD, Leiberg S, et al. (2002). The obsessive compulsive inventory: development and validation of a short version. Psychol Assess 14: 485–496.
Foa EB, Kozak J (1996). Psychological treatment for obsessive compulsive disorder. In Mavissakalian MR, Prien RF (eds.) Long-term Treatments of Anxiety Disorders (pp. 285–309). Washington DC: American Psychiatric Press.
Foa EB, Kozak MJ (1997). Mastery of Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach (Therapist Guide). New York: Oxford University Press.
Foa EB, Kozak MJ, Goodman WK, et al. (1995). DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry 152: 90–96.
Foa EB, Kozak MJ, Goodman WK, et al. (1995). DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry 152: 90–96.
Foa EB, Kozak MJ, Steketee G, McCarthy PR (1992). Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Br J Clin Psychol 31: 279–292.
Foa EB, Kozak MJ, Steketee GS, McCarthy PR (1992). Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Br J Clin Psychol 31: 279–292.
Foa, EB, Liebowitz MR, Kozak MJ, et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162: 151–161.
Folette VM, Smith AA (2005). Exposure therapy. In Freeman A, Felgoise SH, Nezu CM, Nezu AM, Reinecke MA (eds.) Encyclopedia of Cognitive Behavior Therapy (pp.185–187). New York: Springer.
Fontenelle LF, Mendlowicz MV, Soares ID, Viersiani M (2004). Patients with obsessive-compulsive disorder and hoarding symptoms: a distinct clinical subtype? Compr Psychiatry 45: 375–383.
Fontenelle LF, Nascimento AL, Mendlowicz MV, Shavitt RG, Versiani M (2007). An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 8: 563–583.
Frankenburg FR (1984). Hoarding in anorexia nervosa. Br J Med Psychol 57: 57–60.
Franklin M, Kozak M, Cashman L, et al. (1998). Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial. J Am Acad Child Adolesc Psychiatry 37: 412–419.
Franklin ME, Abramowitz JS, Kozak MJ, Levine J, Foa EB (2000). Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: a comparison of randomized and clinic patients. J Consult Clin Psychol 68: 594–602.
Franklin ME, Kozak MJ, Cashman LA, et al. (1998). Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial. J Am Acad Child Adolesc Psychiatry 37: 412–419.
Frare F, Perugi G, Ruffolo G, et al. (2004). Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features. Eur Psychiatry 19: 292–298.
Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ (1994). Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55: 301–305.
Freeman JB, Garcia AM (2008). Family Based Treatment for Young Children with OCD: Therapist Guide. New York: Oxford University Press.
Freeman W, Watts JW, Hunt T (1942). Psychosurgery; Intelligence, Emotion and Social Behavior Following Prefrontal Lobotomy for Mental Disorders. Springfield, IL: Charles C. Thomas.
Freeston MH, Rheaume J, Ladouceur R (1996). Correcting faulty appraisals of obsessional thoughts. Behav Res Ther 34: 433–446.
Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD (2007). Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry 68: 972–973.
Frost RO, Gross R (1993). The hoarding of possessions. Behav Res Ther 31: 367–382.
Frost RO, Hartl T, Christian R, Williams N (1995). The value of possessions in compulsive hoarding: patterns of use and attachment. Behav Res Ther 33: 897–902.
Frost RO, Hartl TL (1996). A cognitive-behavioral model of compulsive hoarding. Behav Res Ther 34: 341–350.
Frost RO, Kim HJ, Morris C, et al. (1998). Hoarding, compulsive buying and reasons for saving. Behav Res Ther 36: 657–664.
Frost RO, Krause MS, Steketee G (1996). Hoarding and obsessive-compulsive symptoms. Behav Modif 20: 116–132.
Frost RO, Meagher BM, Riskind JH (2001). Obsessive-compulsive features in pathological lottery and scratch ticket gamblers. J Gambling Studies 17: 5–19.
Frost RO, Shows DL (1993). The nature and measurement of compulsive indecisiveness. Behav Res Ther 31: 683–692.
Frost RO, Steketee G, Grisham J (2004). Measurement of compulsive hoarding: Saving Inventory-Revised. Behav Res Ther 42: 1163–1182.
Frost RO, Steketee G, Tolin DF, Brown TA (2006). Comorbidity and diagnostic issues in compulsive hoarding. In Proceeding of the Annual Meeting of the Anxiety Disorders Association of America, Miami, March.
Frost RO, Steketee G, Tolin DF, Renaud S (2008). Development and validation of the Clutter Image Rating. J Psychopathol Behav Assess 32: 401–417.
Frost RO, Steketee G, Williams L (2000). Hoarding: a community health problem. Health Social Care Community 8: 229–234.
Frost RO, Steketee G, Williams L (2002). Compulsive buying, compulsive hoarding, and obsessive-compulsive disorder. Behav Ther 33: 201–214.
Frost RO, Tolin DF (2008). Compulsive hoarding. In Abramowitz JS, Taylor S, McKay D (eds.) Clinical Handbook of Obsessive-Compulsive Disorder and Related Problems. (pp. 76–94). Baltimore, MD: Johns Hopkins University Press.
Frost RO, Tolin DF, Steketee G, Fitch KE, Selbo-Bruns A (2009). Excessive acquisition in hoarding. J Anxiety Disord 23: 632–639.
Fukuda O (1977). Statistical analysis of dysmorphophobia in out-patient clinic. Jpn J Plast Reconstruct Surg 20: 569–577.
Gabriel A (2001). A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can J Psychiatry 46: 285–286.
Gallup Organization (1993). A Gallup Study of Obsessive Compulsive Disorder Sufferers. Princeton, NJ: Gallup Organization.
Garber A, Gregory RJ (1997). Benztropine in the treatment of venlafaxine induced sweating. J Clin Psychiatry 58: 176–177.
Geller DA (2006). Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr Clin N Am 29: 353–370.
Geller DA, Biederman J, Jones J, et al. (1998). Obsessive-compulsive disorder in children and adolescents: a review. Harv Rev Psychiatry 5: 260–273.
Geller DA, Biederman J, Stewart SE, et al. (2003a). Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 160: 1919–1928.
Geller DA, Biederman J, Stewart SE, et al. (2003b). Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 13(Suppl 1): S19–S29.
Geller DA, Hoog SL, Heiligenstein JH, et al. (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40: 773–779.
Geller DA, Petty C, Vivas F, et al. (2007). Further evidence for co-segregation between pediatric obsessive compulsive disorder and attention deficit hyperactivity disorder: a familial risk analysis. Biol Psychiatry 61: 1388–1394.
George MS, Trimble MR, Ring HA, Sallee FR, Robertson MM (1993). Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. Am J Psychiatry 150: 93–97.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacol 156: 117–154.
Gilbert AR, Keshavan MS, Diwadkar V, et al. (2008). Gray matter differences between pediatric obsessive-compulsive disorder patients and high-risk siblings: a preliminary voxel-based morphometry study. Neurosci Lett 435: 45–50.
Ginsburg GS, Kingery JN, Drake KL, Grados MA (2008). Predictors of treatment response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 47: 868–878.
Ginsburg GS, Kingery JN, Drake KL, Grados MA (2008). Predictors of treatment response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 47: 868–878.
Glick ID, Poyurovsky M, Ivanova O, Koran LM (2008). Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. J Clin Psychiatry 69: 1856–1859.
Goddard AW, Shekhar A, Whiteman AF, McDougle CJ (2008). Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 13: 325–332.
Goff DC, Keefe R, Citrome L, et al. (2007). Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27: 582–589.
Goodman WK (1999). Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 60(Suppl 18): 18: 27–32.
Goodman WK, Kozak MJ, Liebowitz M, White KL (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11: 21–29.
Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH (1993). Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54(Suppl): 16–26.
Goodman WK, Price LH (1992). Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin N Am 15: 861–869.
Goodman WK, Price LH, Rasmussen SA, et al. (1989). Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 46: 36–44.
Goodman WK, Price LH, Rasmussen SA, et al. (1989). The Yale–Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012–1016.
Goodman WK, Price LH, Rasmussen SA, et al. (1989). The Yale–Brown Obsessive Compulsive Scale: II Validity. Arch Gen Psychiatry 46: 1012–1016.
Goodman WK, Price LH, Rasmussen SA, et al. (1989). The Yale–Brown Obsessive-Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011.
Goodman WK, Price LH, Rasmussen SA, et al. (1989a). The Yale–Brown obsessive compulsive scale: II validity. Arch Gen Psychiatry 46: 1006–1011.
Goodman WK, Price LH, Rasmussen SA, et al. (1989b). The Yale–Brown obsessive compulsive scale: II validity. Arch Gen Psychiatry 46: 1012–1016.
Goodwin DW, Guze SB, Robbins E (1969). Follow-up studies in obsessional neurosis. Arch Gen Psychiatry 20: 182–187.
Goodwin RD, Amador XF, Malaspina D, et al. (2003). Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res 61: 89–95.
Gordon A, Rasmussen SA (1988). Mood related obsessive compulsive symptoms in a patient with bipolar affective disorder. J Clin Psychiatry 49: 27–28.
Grados M, Riddle MA (2008). Do all obsessive-compulsive disorder subtypes respond to medication? Int Rev Psychiatry 20: 189–193.
Gram LF, Hansen MG, Sindrup SH, et al. (1993). Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 15: 18–24.
Grant JE, Kim SW, Crow SJ (2001). Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. J Clin Psychiatry 62: 517–522.
Grant JE, Kim SW, Eckert ED (2002). Body dysmorphic disorder in patients with anorexia nervosa: prevalence, clinical features, and delusionality of body image. Int J Eat Disord 32: 291–300.
Grant JE, Mancebo MC, Pinto A, et al. (2007). Late-onset obsessive compulsive disorder: clinical characteristics and psychiatric comorbidity. Psychiatry Res 30 152: 21–27.
Grant JE, Menard W, Pagano ME, et al. (2005). Substance use disorders in individuals with body dysmorphic disorder. J Clin Psychiatry 66: 309–316.
Grant JE, Menard W, Phillips KA (2006). Pathological skin picking in individuals with body dysmorphic disorder. Gen Hosp Psychiatry 28: 487–493.
Grant JE, Odlaug BL (2008). Challenges in diagnosing and treating obsessive-compulsive disorder. Psychiatric Times 25(Suppl 2): 25–30.
Grant JE, Odlaug BL, Kim SW (2009). N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo controlled study. Arch Gen Psychiatry 66: 756–763.
Grant JE, Odlaug BL, Kim SW (2009). N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 66: 756–763.
Grant P, Lougee L, Hirschtritt M, Swedo S (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Child Adolesc Psychopharmacol 17: 761–767.
Grant P, Lougee L, Hirschtritt M, Swedo SE (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17: 761–767.
Grant P, Lougee L, Hirschtritt M, Swedo SE (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17: 761–767.
Green AI, Canuso CM, Brenner MJ, Wojcik JD (2003). Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin N Am 26: 115–139.
Greenberg BD, Dougherty DD, Rauch SL. (2009). Neurosurgical treatments: lesion procedures and deep brain stimulation. In Sadock BJ, Sadock VA, Ruiz P (eds.) Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Ninth edition (pp. 3314–3322). Philadelphia, PA: Lippincott, Williams & Wilkins.
Greenberg BD, Gabriels LA, Malone DA, Jr., et al. (2010). Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 15: 64–79.
Greenberg D (1987). Compulsive hoarding. Am J Psychother 41: 409–416.
Greenberg D, Witztum E, Levy A (1990). Hoarding as a psychiatric symptom. J Clin Psychiatry 51: 417–421.
Greist J, Chouinard G, DuBoff E, et al. (1995c). Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289–295.
Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995a). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 52: 53–60.
Greist JH, Jenike MA, Robinson D, Rasmussen SA (1995b). Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double blind, placebo controlled trial. Eur J Clin Res 7: 195–204.
Griest JH, Marks IM, Baer L, et al. (2002). Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 63: 138–145.
Grillo CM, McGlashan TH, Morey LC, et al. Internal consistency, intercriterion overlap and diagnostic efficiency of criteria sets for dsm-iv schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Acta Psychiatr Scand 104: 264–272.
Grisham JR, Brown TA, Liverant GI, Campbell-Sills L (2005). The distinctiveness of compulsive hoarding from obsessive-compulsive disorder. J Anxiety Disord 19: 767–779.
Grisham JR, Brown TA, Savage CR, Steketee G, Barlow DH (2007). Neuropsychological impairment associated with compulsive hoarding. Behav Res Ther 45: 1471–1483.
Grisham JR, Frost RO, Steketee G, Kim HJ, Hood S (2006). Age of onset of compulsive hoarding. J Anxiety Disord 20: 675–686.
Grohol JM (2004). What to Look for in Quality Online Support Groups. http://psychcentral.com/archives/support_groups.htm (accessed 12 August 2010).
Grunes MS, Neziroglu F, McKay D (2001). Family involvement in the behavioral treatment of obsessive-compulsive disorder: a preliminary investigation. Behav Ther 32: 803–820.
Gunnell D, Saperia J, Ashby D (2005). Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 330: 385.
Gunstad J, Phillips KA (2003). Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry 44: 270–276.
Gur RC, Ragland JD, Mozley LH, et al. (1997). Lateralized changes in regional cerebral blood flow during performance of verbal and facial recognition tasks: correlations with performance and “effort.” Brain Cogn 33: 388–414.
Guy W (1976). Assessment Manual for Psychopharmacology. Washington, DC: US Government Printing Office.
Hachman A, McLean C (1975). A comparison of flooding and thought stopping in the treatment of obsessional neurosis. Behav Res Ther 34: 47–51.
Hafner RJ (1998). Obsessive–compulsive disorder: a questionnaire survey of a self-help group. Int J Soc Psychiatry 34: 310−315.
Hand I, Tichatzky M (1979). Behavioral group therapy for obsessions and compulsions: First results of a pilot study. In Sjoden PO, Bates D, Dockens WS (eds.) Trends in Behavioral Therapy (pp. 269–297). New York: Academic Press,
Hankin CS, Koran LM, Bronstone A, et al. (2009). Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. CNS Spectr 14: 695–703.
Hanna G (1995). Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 34: 19–27.
Hanna GL, Himle JA, Curtis GC, et al. (1998). Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 18: 102–111.
Hanna GL, Himle JA, Curtis GC, Gillespie BW (2005). A family study of obsessive-compulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet 134: 13–19.
Harris EC, Barraclough B (1997). Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 170: 205–228.
Hartl TL, Duffany SR, Allen GJ, Steketee G, Frost RO (2005). Relationships among compulsive hoarding, trauma, and attention-deficit/hyperactivity disorder. Behav Res Ther 43: 269–276.
Hartl TL, Frost RO (1999). Cognitive-behavioral treatment of compulsive hoarding: a multiple baseline experimental case study. Behav Res Ther 37: 451–461.
Hartl TL, Frost RO, Allen GJ, et al. (2004). Actual and perceived memory deficits in individuals with compulsive hoarding. Depress Anxiety 20: 59–69.
Harvey AT, Preskorn SH (1996). Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16: 345–355.
Hasler G, LaSalle-Ricci V, Ronquillo J (2005). Obsessive-compulsive symptom dimensions show specific relationships to psychiatric comorbiditiy. Psychiatry Res 135: 121–132.
Hasler G, LaSalle-Ricci VH, Ronquillo JG, et al. (2005). Obsessive compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. Psychiatry Res 135: 121.
Hasler G, LaSalle-Ricci VH, Ronquillo JG, et al. (2005). Obsessive-compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. Psychiatry Res 135 121–132.
Hasler G, Pinto A, Greenberg BD, et al. (2007). Familiality of factor analysis-derived YBOCS dimensions in OCD-affected sibling pairs from the OCD Collaborative Genetics Study. Biol Psychiatry 61: 617–625.
Hay P, Sachdev P, Cumming S, et al. (1993). Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 87: 197–207.
Hayes S, Luoma J, Bond F, Masuda A, Lillis J (2006). Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther 44: 1–25.
Hayes SC, Barnes-Holmes D, Roche B (eds.) (2001). Relational Frame Theory: A Post-Skinnerian Account of Human Language and Cognition. New York: Kluwer Academic.
Hayes SC, Pierson H (2005). Acceptance and commitment therapy. In Freeman A, Felgoise SH, Nezu CM, Nezu AM, Reinecke MA (eds.) Encyclopedia of Cognitive Behavior Therapy (pp.1–4). New York: Springer.
Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB (2003). Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectr 8: 363–371.
Hemmings S, Stein DJ (2006). The current state of association studies in obsessive-compulsive disorder. Psychiatr Clin N Am 29 411–444.
Henin A, Kendall PC (1997). Obsessive-compulsive disorder in childhood and adolescence. Adv Clin Child Psychol 19: 75–131.
Herner T (1961). Treatment of mental disorders with frontal stereotactic thermo-lesions: a follow-up of 116 cases. Acta Psychiatr Scand 58(Suppl 36): 1–140.
Hewlett WA, Schmid SP, Salomon RM (2003). Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 64: 1025–1030.
Hibbs ED, Hamburger SD, Lenane M, et al. (1991). Determinants of expressed emotion in families of disturbed and normal children. J Child Psychol Psychiatry 32: 757–770.
Hiemke C, Weigmann H, Härtter S, et al. (1994). Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14: 279–281.
Higuchi H, Kamata M, Yoshimoto M, Shimizu T, Hishikawa Y (1999). Panic attacks in patients with chronic schizophrenia: A complication of long-term neuroleptic treatment. Psychiatry Clin Neurosci 53: 91–94.
Himle JA, Fischer DJ, Van Etten ML, Janeck AS, Hanna GL (2003). Group behavioral therapy for adolescents with tic-related and non-tic-related obsessive-compulsive disorder. Depress Anxiety 17: 73–77.
Hoch P, Polatin P (1949). Pseudoneurotic forms of schizophrenia. Psychiatry Q 23: 248–276.
Hocking B (2003). Reducing mental illness stigma and discrimination-everybody's business. Med J Aust 178: S47–S48.
Hodgson R, Rachman S, Marks I (1972). The treatment of chronic obsessive-compulsive neurosis: Follow-up and further findings. Behav Res Ther 10: 181–189.
Hoehn-Saric R, Pearlson GD, Harris GJ, et al. (1991). Effects of fluoxetine on regional cerebral blood flow in obsessive compulsive patients. Am J Psychiatry 148: 1243–1245.
Hollander E (1993). Obsessive-compulsive spectrum disorders: an overview. Psychiatr Ann 23: 355–358.
Hollander E, Allen A, Kwon J, et al. (1999). Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56: 1033–1039.
Hollander E, Allen A, Steiner M, et al. (2003b). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64: 1113–1121.
Hollander E, Baldini Rossi N, Sood E, Pallanti S (2003). Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6: 397–401.
Hollander E, Bienstock CA, Koran LM, et al. (2002). Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 63(Suppl 6): 20–29.
Hollander E, Cohen L (1996). Psychobiology and psychopharmacology of compulsive spectrum disorders. In Oldham JM, Hollander E, Skodol AE (eds.) Impulsivity and Compulsivity (pp. 143–166). Washington, DC: American Psychiatric Press.
Hollander E, Cohen L, Simeon D (1993). Body dysmorphic disorder. Psychiatr Ann 23: 359–364.
Hollander E, Cohen LJ, Simeon D (1993). Body dysmorphic disorder. Psychiatr Ann 23: 359–364.
Hollander E, Friedberg J, Wasserman S, et al. (2003c). Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 64: 546–550.
Hollander E, Kim S, Khanna S, Pallanti S (2007). Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectr 12(Suppl 3): 5–13.
Hollander E, Koran LM, Goodman WK, et al. (2003a). A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64: 640–647.
Hollander E, Kwon K, Stein DJ, et al. (1996). Obsessive-compulsive and spectrum disorders: Overview and quality of life issues. J Clin Psychiatry 57(Suppl 8): 3–6.
Hollander E, Wong C (1995). Obsessive compulsive spectrum disorders. J Clin Psychiatry 56: 3–6.
Hollander E, Wong C (1998). Psychosocial function and economic cost of obsessive-compulsive disorder. CNS Spectr 3: 48–58.
Holzer JC, Goodman WK, McDougle CJ, et al. (1994). Obsessive-compulsive disorder with and without a chronic tic disorder: a comparison of symptoms in 70 patients. Br J Psychiatry 164: 469–473.
Hong J, Samuels J, Bienvenu OJ, et al. (2004). Clinical correlates of recurrent major depression in obsessive-compulsive disorder. Depress Anxiety 20: 86–91.
Honigman RJ, Phillips KA, Castle DJ (2004). Psychosocial outcomes for patients seeking cosmetic surgery: oppurtunities and risks. Plast Reconstr Surg 113: 1229–1237.
Hoogduin CAL, Duivenvoorden HJ (1988). A decision model in the treatment of obsessive compulsive neuroses. Br J Psychiatry 152: 515–521.
Hooley JM, Teasdale JD (1989). Predictors of relapse in unipolar depressives: expressed emotion, marital distress, and perceived criticism. J Abnorm Psychol 98: 229–235.
Horwath E, Weissman MM (2000). The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatr Clin N Am 23: 493–507.
Humphreys K (2000). Community narratives and personal stories in Alcoholics Anonymous. J Community Psychol 28: 495–506.
Huppert JD, Foa EB (2005). Severe OCD. In Freeman A, Felgoise SH, Nezu CM, Nezu AM, Reinecke MA (eds.) Encyclopedia of Cognitive Behavior Therapy (pp. 347–349). New York: Springer.
Huppert JD, Franklin ME (2005). Cognitive-behavioral therapy for obsessive-compulsive disorder: an update. Curr Psychiatr Rep 7: 268–273.
Husted DS, Shapira NA, Goodman WK (2006). The neurocircuitry of obsessive-compulsive disorder and disgust. Prog Neuropsychopharmacol Biol Psychiatry 30: 389–399.
Husted DS, Shapira NA, Goodman WK (2006). The neurocircuitry of obsessive-compulsive disorder and disgust. Prog Neuropsychopharmacol Biol Psychiatry 30: 389–399.
Hwang JP, Tsai SJ, Yang CH, Liu KM, Lirng JF (1998). Hoarding behavior in dementia. A preliminary report. Am J Geriatr Psychiatry 6: 285–289.
Insel TR, Akiskal HS (1986). OCD with psychotic features: a phenomenological analysis. Am J Psychiatry 143: 1527–1533.
Insel TR, Murphy DL (1981). The psychopharmacological treatment of obsessive-compulsive disorder: a review. J Clin Psychopharmacol 1: 304–311.
Insel TR, Murphy DL, Cohen RM, et al. (1983). Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40: 605–612.
Ivarsson T, Melin K (2008). Autism spectrum traits in children and adolescents with obsessive-compulsive disorder (OCD). J Anxiety Disord 22: 969–978.
Jablensky A (2006). Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 11: 815–836.
Jacobson NS, Truax P (1991). Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59: 12–19.
Jaisoorya TS, Reddy YC, Srinath S (2003). The relationship of obsessive-compulsive disorder to putative spectrum disorders: results from an Indian study. Compr Psychiatry 44: 317–23.
Janet P (1903). Les Obsessions et la Psychasthenie. Paris: Felix Alcan.
Janet P (1903). Les Obsessions et la Psychasthenie. Paris: Felix Alcan.
Jaspers K (1913). General Psychopathology. Berlin: Springer.
Jenike MA, Baer L, Greist JH (1995a). Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10: 122–124.
Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML (1997). Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 154: 1261–1264.
Jenike MA, Baer L, Minichiello WE, Schwartz CE, Carey RJ Jr. (1986). Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 143: 530–532.
Jenike MA, Breiter HC, Baer L, et al. (1996). Cerebral structural abnormalities in obsessive-compulsive disorder: a quantitative morphometric magnetic resonance imaging study. Arch Gen Psychiatry 53: 625–632.
Jenike MA, Breiter HC, Baer L, et al. (1996). Cerebral structural abnormalities in obsessive-compulsive disorder: a quantitative morphometric magnetic resonance imaging study. Arch Gen Psychiatry 53: 625–632.
Jenike MA, Hyman S, Baer L, et al. (1995b). A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 147: 1209–1215.
Jennings KD, Ross S, Pepper S, Elmore M (1999). Thoughts of harming infants in depressed and nondepressed mothers. J Affect Disord 54: 21–28.
Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M (2004). Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 18: 93–104.
Joel D, Doljansky J, Roz N, Rehavi M (2005). Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 130: 25–36.
Külz AK, Meinzer, S, Kopasz M, Voderholzer U (2007). Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology 56: 127–131.
Kalra H, Kamath P, Trivedi JK, Janca A (2008). Caregiver burden in anxiety disorders. Curr Opin Psychiatry 21: 70–3.
Kamath P, Janardhan Reddy YC, Kandavel T (2007). Suicidal behavior in obsessive-compulsive disorder. J Clin Psychiatry 68: 1741–1750.
Kamijima K, Murasaki M, Asai M, et al. (2004). Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci 58: 427–433.
Karno M, Golding JM, Sorenson SB, et al. (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094–1099.
Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094–1099.
Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094–1099.
Katz RJ, DeVeaugh-Geiss J, Landau P (1990). Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28: 401–414.
Kawahara T, Ueda Y, Mitsuyama Y (2000). A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 54: 599–601.
Kayahan B, Ozturk O, Veznedaroglu B, Eraslan D (2005). Obsessive-compulsive symptoms in schizophrenia: prevalance and clinical correlates. Psychiatry Clin Neurosci 59: 291–295.
Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K (2004). Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 161: 2215–2221.
Keijsers GP, Hoogduin CA, Schaap CP (1994). Predictors of treatment outcome in the behavioural treatment of obsessive-compulsive disorder. Br J Psychiatry 165: 781–786.
Kelly D, Richardson A, Mitchell-Heggs N, et al. (1973). Stereotactic limbic leucotomy: a preliminary report on forty patients. Br J Psychiatry 123: 141–148.
Kelly MW, Myers CW (1990). Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. DICP 24: 739–744.
Kessler RC, McGonagle KA, Zhao S, et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.
Ketter TA, Calabrese JR (2002). Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 63: 146–151.
Keuthen NJ, Fraim C, Deckersbach T, et al. (2001). Longitudinal follow-up of naturalistic treatment outcome in patients with trichotillomania. J Clin Psychiatry 62: 101–107.
Keuthen NJ, Makris N, Schlerf JE, et al. (2007). Evidence for reduced cerebellar volumes in trichotillomania. Biol Psychiatry 61: 374–381.
Keuthen NJ, O'Sullivan RL, Ricciardi JN, et al. (1995). The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. Psychother Psychosom 64: 141–145.
Keuthen NJ, Savage CR, O'Sullivan RL, et al. (1996). Neuropsychological functioning in trichotillomania. Biol Psychiatry 39: 747–749.
Khullar A, Chue P, Tibbo P (2001). Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 26: 55–59.
Kiehl KA, Liddle PF, Hopfinger JB (2000). Error processing and the rostral anterior cingulate: an event-related fMRI study. Psychophysiology 37: 216–223.
Kim CH, Chang JW, Koo MS, et al. (2003). Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand 107: 283–290.
Kim CH, Koo MS, Cheon KA, et al. (2003). Dopamine transporter density of basal ganglia assessed with [123I]IPT SPECT in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging 30: 1637–1643.
Kim MC, Lee TK, Choi CR (2002). Review of long-term results of stereotactic psychosurgery. Neurol Med Chir (Tokyo) 42: 365–371.
Kim S-WS, Il-Seon KJ-M, Yang S-J, et al. (2008). Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol 28: 349–352.
Kim SJ, Kim C (2006). The genetic studies of obsessive-compulsive disorder and its future directions. Yonsei Med J 47: 443–454.
Kim SW, Grant JE, Adson DE, Shin YC (2001). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49: 914–921.
Kirk J (1983). Behavioural treatment of obsessional-compulsive patients in routine clinical practice. Behav Res Ther 21: 57–62.
Kishore R, Samar R, Reddy J, Chandrasekhar CR, Thennarasu K (2004). Clinical characteristics and treatment response in poor and good insight obsessive compulsive disorder. Eur Psychiatry 19: 202–208.
Kleinknecht RA, Dinnel DL, Kleinknecht EE, et al. (1997). Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho. J Anxiety Disord 11: 157–177.
Knight G (1973). Further observations from an experience of 660 cases of stereotactic tractotomy. Postgrad Med J 49: 845–854.
Koblenzer CS (1985). The dysmorphic syndrome. Arch Dermatol 121: 780–784.
Kohlmann CW, Schumacher A, Streit R (1988). Trait anxiety and parental child-rearing behavior: support as a moderator variable. Anxiety Res 1: 53–64.
Koponen H, Lepola U, Leinonen E, et al. (1997). Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96: 343–346.
Koran L (2000). Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am 23: 509–517.
Koran LM, Aboujaoude E, Bullock KD, et al. (2005). Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 66: 353–359.
Koran LM, Aboujaoude E, Gamel NN (2009). Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 70: 1530–1535.
Koran LM, Abujaoude E, Large MD, et al. (2008). The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr 13: 316–322.
Koran LM, Hackett E, Rubin A, et al. (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159: 88–95.
Koran LM, McElroy SL, Davidson JR, et al. (1996). Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16: 121–129.
Koran LM, Sallee FR, Pallanti S (1997). Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 154: 396–401.
Koran LM, Thienemann ML, Davenport R, et al. (1996). Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 153: 783–788.
Kordon A, Wahl K, Koch N, et al. (2008). Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28: 550–554.
Kozak M, Foa E (1994). Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder. Behav Res Ther 32: 343–353.
Kozak MJ, Foa EB (1994). Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder. Behav Res Ther 12: 343–353.
Krüger S, Bräunig P, Höffler J, et al. (2000). Prevalence of obsessive-compulsive disorder in schizophrenia and significance of motor symptoms. J Neuropsychiatry Clin Neurosci 12: 16–24.
Kraepelin E (1909–1915). Psychiatrie, 8th edn. Leipzig: JA Barth.
Kringelbach ML (2005). The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci 6: 691–702.
Kringelbach ML, Rolls ET (2004). The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog Neurobiol 72: 341–372.
Krone KP, Himle JA, Nesse RM (1991). A standardized behavioral group treatment program for obsessive-compulsive disorder: preliminary outcomes. Behav Res Ther 29: 627–632.
Kronig MH, Apter J, Asnis G, et al. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19: 172–176.
Krystal JH, Perry EB Jr, Gueorgieva R, et al. (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62: 985–994.
Kuey L (2008). The impact of stigma on somatic treatment and care for people with comorbid mental and somatic disorders. Curr Opin Psychiatry 21: 403–411.
Kullberg G (1977). Differences in effects of capsulotomy and cingulotomy. In Sweet WH, Obrador WS, Martín-Rodríguez JG, eds. Neurosurgical Treatment in Psychiatry, Pain, and Epilepsy (pp. 301–208). Baltimore, MD: University Park Press.
Kushner MG, Won KS, Donahue C, et al. (2007). d-Cycloserine augmented exposure therapy for obsessive compulsive disorder. Biol Psychiatry 62: 835–838.
Kushner MG, Won KS, Donahue C, et al. (2007). d-Cycloserine augmented exposure therapy for obsessive compulsive disorder. Biol Psychiatry 62: 835–838.
Kyrios M, Frost RO, Steketee G (2004). Cognitions in compulsive buying and acquisition. Cogn Ther Res 28: 241–258.
Labad J, Menchon JM, Alonso P, et al. (2008). Gender differences in obsessive-compulsive symptom dimensions. Depress Anxiety 25: 832–838.
Ladee GA (1966). Hypochondriacal Syndromes. Amsterdam: Elsevier.
Lafleur DL, Pittenger C, Kelmendi B, et al. (2006). N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 184: 254–256.
Lafleur DL, Pittenger C, Kelmendi B, et al. (2006). N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 184: 254–256.
Lancet Mental Health Group (2007). Scale up services for mental disorders: a call for action. Lancet 370: 1241–1252.
Lavin MR, Halligan P (1996). ECT for comorbid obsessive-compulsive disorder and schizophrenia. Am J Psychiatry 153: 1652–1653.
Lawrence NS, An KS, Mataix-Cols D, et al. (2007). Neural responses to facial expressions of disgust but not fear are modulated by washing symptoms in OCD. Biol Psychiatry 61: 1072–1080.
Lawrence NS, Wooderson S, Mataix-Cols D, et al. (2006). Decision making and set shifting impairments are associated with distinct symptom dimensions in obsessive-compulsive disorder. Neuropsychology 20: 409–419.
Lawrence NS, Wooderson S, Mataix-Cols D, et al. (2006). Decision making and set shifting impairments are associated with distinct symptom dimensions in obsessive-compulsive disorder. Neuropsychology 20: 409–419.
Leckman JF, Grice DE, Boardman J, et al. (1997). Symptoms of obsessive compulsive disorder. Am J Psychiatry 154: 911–917.
Leckman JF, Rauch SL, Mataix-Cols D (2007). Symptom dimensions in obsessive-compulsive disorder: implications for the DSM-V. CNS Spectr 12: 376–387, 400.
Lee H, Kwon S, Kwon J, Telch M (2005b). Testing the autogenous-reactive model of obsessions. Depress Anxiety 21: 118–129.
Lee HJ, Kim ZS, Kwon SM (2005a). Thought disorder in patients with obsessive-compulsive disorder. J Clin Psychol 61: 401–413.
Lee HJ, Kwon SM (2003). Two different types of obsession: autogenous obsessions and reactive obsessions. Behav Res Ther 41: 11–29.
Lee HJ, Kwon SM, Kwon JS, Telch MJ (2005). Testing the autogenous-reactive model of obsessions. Depress Anxiety 21: 118–129.
Lee HJ, Telch MJ (2005). Autogenous/reactive obsessions and their relationship with OCD symptoms and schizotypal personality features. J Anxiety Disord 19: 793–805.
Lensi P, Cassano G, Correddu G (1996). Obsessive-compulsive disorder: familial-developmental history, symptomatology, comorbidity and course with special reference ti gender-related pathogenetic differences. Br J Psychiatry 169: 101–107.
Leon AC, Portera L, Weissman MM (1995). The social costs of anxiety disorders. Br J Psychiatry 166(Suppl 27): 19–22.
Leonard H, Swedo SE, Lenane MC, et al. (1993). A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50: 429–439.
Leonard HL, Ale CM, Freeman JB, Garcia AM, Ng JS (2005). Obsessive-compulsive disorder. Child Adolesc Psychiatr Clin N Am 14: 727–743, viii.
Leonard HL, Lenane MC, Swedo SE, Rettew DC, Rapoport JL (1991). A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry 48: 821–827.
Leonard HL, Swedo S, Lenane M, et al. (1993). A two- to seven-year follow-up study of 54 obsessive compulsive children and adolescents. Arch Gen Psychiatry 50: 429–439.
Leonard HL, Swedo S, Rapoport JL, Coffey M, Cheslow D (1988). Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 24: 93–95.
Leonard HL, Swedo SE, Lenane MC, et al. (1993). A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50: 429–439.
Leonard HL, Swedo SE, Rapoport JL, et al. (1989). Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 46: 1088–1092.
Levitan RD, Kaplan AS, Masellis M, et al. (2006). The serotonin-1Dbeta receptor gene and severity of obsessive-compulsive disorder in women with bulimia nervosa. Eur Neuropsychopharmacol 16: 1–6.
Lewin AB, Storch EA, Merlo LJ, et al. (2005), Intensive cognitive behavioral therapy for pediatric obsessive compulsive disorder: a treatment protocol for mental health providers. Psychol Serv 2: 91Y104.
Li X, May RS, Tolbert LC, et al. (2005). Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 66: 736–743.
Liebowitz MR, Turner SM, Piacentini J, et al. (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41: 1431–1438.
Liebowitz MR, Turner SM, Piacentini J, et al. (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41: 1431–1438.
Lim M, Park DY, Kwon JS, Joo YH, Hong KS (2007). Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 27: 712–713.
Lindsay M, Crino R, Andrews G (1997). Controlled trial of exposure and response prevention in obsessive compulsive disorder. Br J Psychiatry 171: 135–139.
Linehan MM (1993). Skills Training Manual for Treating Borderline Personality Disorder. New York: Guilford Press.
Livingston-Van Noppen B, Rasmussen SA, Eisen J, McCarthey L (1990). Family function and treatment in obsessive-compulsive disorder. In Jenike MA, Baer L, Minichiello WE (eds.) Obsessive Compulsive Disorders: Theory and Management (pp. 325–340). Chicago, IL: Yearbook Medical.
Lochner C, Kinnear CJ, Hemmings SM, et al. (2005). Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. J Clin Psychiatry 66: 1155–1160.
Lochner C, Seedat S, Niehaus DJ, Stein DJ (2006). Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol 21: 255–259.
Lopes AC, Greenberg BD, Noren G, et al. (2009): Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective study. J Neuropsychiatry Clin Neurosci 21: 381–392.
Lopez-Ibor JJ Jr., Saiz J, Cottraux J, et al. (1996). Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 6: 111–118.
Luchian SA, McNally RJ, Hooley JM (2007). Cognitive aspects of nonclinical obsessive-compulsive hoarding. Behav Res Ther 45: 1657–1662.
Luchins DJ, Goldman MB, Lieb M, Hanrahan P (1992). Repetitive behaviors in chronically institutionalized schizophrenic patients. Schizophr Res 8: 119–123.
Lucksted A, Stewart B, Forbes CB (2008). Benefits and changes for family to family graduates. Am J Community Psychol 42: 154–166.
Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003). Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Progr Neuropsychopharmacol Biol Psychiatry 27: 333–346.
Lysaker PH, Bryson GJ, Marks KA, Greig TC, Bell MD (2002). Association of obsessions and compulsions in schizophrenia with neurocognition and negative symptoms. J Neuropsychiatry Clin Neurosci 14: 449–453.
Lysaker PH, Marks KA, Picone JB, et al. (2000). Obsessive and compulsive symptoms in schizophrenia. Clinical and neurocognitive correlates. J Nerv Ment Dis 188: 78–83.
Machlin SR, Harris GJ, Pearlson GD, et al. (1991). Elevated medial-frontal cerebral blood flow in obsessive compulsive patients: a SPECT study. Am J Psychiatry 148: 1240–1242.
Magliano L, Tosini P, Guarneri M, Marasco C, Catapano F (1996). Burden on the families of patients with obsessive-compulsive disorder: a pilot study. Eur Psychiatry 11: 192–197.
Maguire EA, Mummery CJ (1999). Differential modulation of a common memory retrieval network revealed by positron emission tomography. Hippocampus 9: 54–61.
Mahendran R, Liew E, Subramaniam M (2007). De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizo-affective disorder: a retrospective cross-sectional study. J Clin Psychiatry 68: 542–545.
Maier N (1949). Frustration: The Study of Behavior Without a Goal. New York: McGraw-Hill.
Maina G, Albert H, Pessina E, Bogetto F (2007). Bipolar obsessive-compulsive disorder and personality disorders. Bipolar Disord 9: 722–729.
Maina G, Albert U, Salvi V, Bogetto F (2004). Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 65: 1365–1371.
Maina G, Pessina E, Albert U, Bogetto F (2008). Eight-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 18: 364–372.
Mallet L, Polosan M, Jaafari N, et al. (2008). Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 359: 2121–2134.
Maltby N, Tolin DF, Worhunsky P, O'Keefe TM, Kiehl KA (2005). Dysfunctional action monitoring hyperactivates frontal–striatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage 24: 495–503.
Malti T, Noam GG (2008). The hidden crisis in mental health and education: the gap between student's needs and existing supports. New Direct Youth Dev 120: 13–29.
Mamo D, Graff A, Mizrahi R, et al. (2007). Differential effects of Aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164: 1411–1417.
Mansueto CS, Stemberger RM, Thomas AM, Golomb RG (1997). Trichotillomania: a comprehensive behavioral model. Clin Psychol Rev 17: 567–577.
Marazziti D, Dell'Osso L, Gemignani A, et al. (2001). Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 16: 215–219.
Marazziti D, Pfanner C, Dell'Osso B, et al. (2005). Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol 19: 392–394.
March J, Frances A, Kahn D, Carpenter D (1997a). Expert consensus guidelines: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58: 1–72.
March J, Mulle K (1998). OCD in Children and Adolescents: A Cognitive-Behavioral Treatment Manual. New York: Guilford Press.
March J, Mulle K, Herbel B (1994). Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven package. J Am Acad Child Adolesc Psychiatry 33: 333–341.
March J, Parker J, Sullivan K, Stallings P, Conners K (1997b). The Multidimensional Anxiety Scale for Children (MASC). J Am Acad Child Adolesc Psychiatry 36: 554–565.
March JS (2004). Cognitive-behavioral therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292: 1969–1976.
March JS, Biederman J, Wolkow R, et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280: 1752–1756.
March JS, Biederman J, Wolkow R, et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280: 1752–1756.
March JS, Frances A, Carpenter D, et al. (1997). The Expert Consensus Guidelines Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl 4): 1–72.
March JS, Frances A, Carpenter D, Kahn DA (1997). The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl 4): 3–72.
March JS, Franklin ME, Leonard H, et al. (2007). Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 61: 344–347.
March JS, Mulle K, Herbel B (1994). Behavioral psychotherapy for children and adolescents with obsessive–compulsive disorder: an open trial of a new protocol driven treatment package. J Am Acad Child Adolesc Psychiatry 33: 333−341.
Marcy TR, Britton ML (2005). Antidepressant-induced sweating. Ann Pharmacother 39: 748–752.
Marek GJ, Carpenter LL, McDougle CJ, Price LH (2003). Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402–412.
Margetis B (2008). Aggravation of schizophrenia by clomipramine in a patient with comorbid obsessive-compulsive disorder. Psychopharmacol Bull 41: 9–11.
Marks IM, Baer L, Greist JH, et al. (1998). Home self-assessment of obsessive-compulsive disorder. Use of a manual and a computer-conducted telephone interview: two UK–US studies. Br J Psychiatry 172: 406–412.
Marks IM, Hodgson R, Rachman S (1975). Treatment of chronic obsessive-compulsive neurosis by in vivo exposure. Br J Psychiatry 127: 349–364.
Marks IM, Hodgson R, Rachman S (1975). Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure: a two-year follow-up and issues in treatment. Br J Psychiatry 527: 349–364.
Marks IM, Lelliott PT, Basoglu M, et al. (1988). Clomipramine, self-exposure, and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 152: 522–534.
Marks IM, Stern R, Mawson D, Cobb J, McDonald R (1980). Clomipramine and exposure for obsessive-compulsive rituals I. Br J Psychiatry 136: 1–25.
Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980). Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 136: 1–25.
Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980). Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 136: 1–25.
Martin A, Scahill L, Vitulano L, King RA (1998). Stimulant use and trichotillomania. J Am Acad Child Adolesc Psychiatry 37: 349–350.
Martin JL, Thienemann M (2005). Group cognitive-behavior therapy with family involvement for middle-school-age children with obsessive-compulsive disorder: a pilot study. Child Psychiatry Hum Dev 36: 113–127.
Masellis M, Rector NA, Richter MA (2003). Quality of life in OCD: differential impact of obsessions, compulsions, and depression comorbidity. Can J Psychiatry 48: 72–77.
Masi G, Millepiedi S, Mucci M, et al. (2005). A naturalistic study of referred children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 44: 673–681.
Masi G, Perugi G, Millepiedi S, et al. (2007). Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications. J Child Adolesc Psychopharmacol 17: 475–486.
Mataix-Cols D (2006). Deconstructing obsessive-compulsive disorder: a multidimensional perspective. Curr Opin Psychiatry 19: 84–89.
Mataix-Cols D, Baer L, Rauch SL, Jenike MA (2000). Relation of factor-analyzed symptom dimensions of obsessive-compulsive disorder to personality disorders. Acta Psychiatr Scand 102: 199–202.
Mataix-Cols D, Marks I, Greist J, Kobak K, Baer L (2002). Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: Results from a controlled trial. Psychother Psychosomat 71: 255–262.
Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L (2002). Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosomat 71: 255–262.
Mataix-Cols D, Nakatani E, Micali N, Heyman I (2008). Structure of obsessive-compulsive symptoms in pediatric OCD. J Am Acad Child Adolesc Psychiatry 47: 773–778.
Mataix-Cols D, Pertusa A, Leckman JF (2007). Issues for DSM-V: how should obsessive-compulsive and related disorders be classified? Am J Psychiatry 164: 1313–1314.
Mataix-Cols D, Rauch S, Baer L, et al. (2002). Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry 159: 263–268.
Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L (1999). Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 156: 1409–1416.
Mataix-Cols D, Rosario-Campos MC, Leckman JF (2005). A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 162: 228–238.
Mataix-Cols D, Rosario-Campos MC, Leckman JF (2005). A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 162: 228–238.
Mataix-Cols D, van den Heuvel OA (2006). Common and distinct neural correlates of obsessive-compulsive and related disorders. Psychiatr Clin N Am 29: 391–410, viii.
Math SB, Reddy CJ (2007). Issues in the pharmacological treatment of obsessive-compulsive disorder. J Clin Pract 61: 1188–1197.
Matsunaga H, Kiriike N, Matsui T, et al. (2000). Gender differences in social and interpersonal features and personality disorders among Japanese patients with obsessive-compulsive disorder. Compr Psychiatry 41: 266–272.
Matsunaga H, Kiriike N, Matsui T, et al. (2002). Obsessive-compulsive disorder with poor insight. Compr Psychiatry 43: 150–157.
Matsunaga H, Kiriike N, Matsui T, et al. (2002). Obsessive-compulsive disorder with poor insight. Compr Psychiatry 43: 150–157.
Matsunaga H, Kiriike N, Matsui T, Oya K, Iwasaki Y (2002). Obsessive-compulsive disorder with poor insight. Compr Psychiatry 43: 150–157.
Matsunaga H, Seedat S (2007). Obsessive-compulsive spectrum disorders: cross-national and ethnic issues. CNS Spectr 12: 392–400.
Mattes JA (1986). A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1: 170–173.
Mavissakalian M, Turner SM, Michelson L (1985). Future directions in the assessment and treatment of obsessive compulsive disorder. In Mavissakalian M, Turner SM, Michelson L (eds.) Obsessive-Compulsive Disorder: Psychological and Pharmacological Treatment (pp. 213–228). New York: Plenum Press.
Mavissakalian MR, Perel JM (2000). The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol 20: 547–555.
Mawson D, Marks IM, Romm L (1982). Clomipramine and exposure for chronic obsessive compulsive disorders: two year follow-up and further findings. Br J Psychiatry 140: 11–18.
McDougle CJ, Barr LC, Goodman WK, et al. (1995b). Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152: 1812–1814.
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57: 794–801.
McDougle CJ, Fleischmann RL, Epperson CN, et al. (1995a). Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 56: 526–528. [Comment in J Clin Psychiatry 1996 57: 594–595.]
McDougle CJ, Goodman WK, Leckman JF, et al. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51: 302–308.
McDougle CJ, Goodman WK, Price LH, et al. (1990). Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147: 652–654.
McDougle CJ, Goodman WK, Price LH, et al. (1990). Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147: 652–654.
McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 11: 175–184.
McElroy, SL, Phillips, KA, Keck, P (1994). Obsessive-compulsive spectrum disorders. J Clin Psychiatry 55(Suppl 10): 33–51.
McGuire PK, Bench CJ, Frith CD, et al. (1994). Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 164: 459–468.
McKay D (2006). Treating disgust reactions in contamination-based obsessive-compulsive disorder. J Behav Ther Exp Psychiatry 37: 53–59.
McKay D, Abramowitz JS, Calamari JE, et al. (2004). A critical evaluation of obsessive-compulsive disorder subtypes: Symptoms versus mechanisms. Clin Psychol Rev 24: 283–313.
McKay D, Neziroglu F (1996). Social skills training in a case of obsessive compulsive disorder with schizotypal personality disorder. J Behav Ther Exp Psychiatry 27: 189–194.
McKay D, Neziroglu F (2009). Methodological issues in the obsessive compulsive spectrum. Psychiatry Res 170: 61–65.
McKay D, Neziroglu F, Yaryura-Tobias JA (1997). Comparison of clinical characteristics in obsessive compulsive disorder and body dysmorphic disorder. J Anxiety Disord 11: 447–454.
McKay D, Neziroglu F, Yaryura-Tobias JA (1997b). Comparison of clinical characteristics in obsessive-compulsive disorder and body dysmorphic disorder. J Anxiety Disord 11: 447–454.
McKay D, Todaro J, Neziroglu F, et al. (1997a). Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther 35: 67–70.
Meghani SR, Penick EC, Nickel EJ, et al. (1998). Schizophrenia patients with and without OCD. In Proceedings of the 151st Annual Meeting of the American Psychiatric Association, Toronto.
Meira-Lima I, Shavitt RG, Miguita K, et al. (2004). Association analysis of the catechol-O-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Genes Brain Behav 3: 75–79.
Metin O, Yazici K, Tot S, Yazici AE (2003). Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 18: 463–467.
Meunier SA, Tolin DF, Frost RO, Steketee G, Brady RE (2006). Prevalence of hoarding symptoms across the anxiety disorders. In Proceeding of the the Annual Meeting of the Anxiety Disorders Association of America, Miami, March.
Meyer V (1966). Modification of expectations in cases with obsessional rituals. Behav Res Ther 4: 273–280.
Miguel EC, Leckman JF, Rauch S, et al. (2005). Obsessive compulsive disorder phenotypes: Implications for genetic studies. Mol Psychiatry 10: 258–275.
Miller WR, Rollnick S (2002). Motivational Interviewing. New York: Guilford Press.
Mills HL, Stewart A, Barlow DH, Mills JR (1973). Compulsive rituals treated by response prevention: an experimental analysis. Arch Gen Psychiatry 28: 524–529.
Mindus P, Ericson K, Greitz T (1986). Regional cerebral glucose metabolism in anxiety disorders studied with positron emission tomography before and after psychosurgical intervention. A preliminary report. Acta Radiol Suppl 369: 444–448.
Mindus P, Rasmussen SA, Lindquist C (1994). Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J Neuropsychiatry Clin Neurosci 6: 467–477.
Modell JG, Mountz JM, Curtis GC, Greden JF (1989). Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1: 27–36.
Mohr N, Vythilingum B, Emsley RA, Stein DJ (2002). Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 17: 37–40.
Montgomery SA (1980). Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceut Med 1: 189–192.
Montgomery SA (1998). Psychopharmacology of obsessive-compulsive disorder. CNS Spectr 3(Suppl 1): 33–37.
Montgomery SA, Kasper S, Stein DJ, Bang HK, Lemming OM (2001). Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16: 75–86.
Montgomery SA, McIntyre A, Osterheider M, for the Lilly European OCD Study Group (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3: 143–152.
Moret C, Isaac M, Briley M (2009). Problems associated with long term treatment of selective serotonin reuptake inhibitors. J Psychopharmacol 23: 967–974.
Morselli E (1891). Sulla dismorfofobia e sulla tafefobia. Boll R Accad Genova 6: 110–119.
Mowrer H (1947). On the dual nature of learning: A reinterpretation of conditioning and problem solving. Harvard Educ Rev 17: 102–148.
Mueller A, Mueller U, Albert P, et al. (2007). Hoarding in a compulsive buying sample. Behav Res Ther 45: 2754–2763.
Mukaddes NM, Abali O, Kaynak N (2003). Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci 57: 405–408.
Mukhopadhaya K, Krishnaiah R, Taye T, et al. (2009). Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J Psychopharmacol 23: 6–13.
Mullins S, Spence SA (2003). Re-examining thought insertion. Semi-structured literature review and conceptual analysis. Br J Psychiatry 182: 293–298.
Mundo E, Bianchi L, Bellodi L (1997). Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 17: 267–271.
Mundo E, Maina G, Uslenghi C (2000). Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 15: 69–76.
Mundo E, Rouillon F, Figuera ML, Stigler M (2001). Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 16: 461–446.
Murphy ML, Pichichero ME (2002). Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med 156: 356–361.
Murphy TK, Sajid MW, Goodman WK (2006). Immunology of obsessive-compulsive disorder. Psychiatr Clin N Am 29 445–469.
Murphy TK, Segarra A, Storch EA, Goodman WK (2008). SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 20: 203–208.
Murphy TK, Segarra A, Storch EA, Goodman WK (2008). SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 20: 203–208.
Murray CJ, Lopez AD (1996). The Global Burden of Disease. Boston, MA: Harvard University Press;.
Nakaaki S, Murata Y, Sato J, et al. (2007). Impairment of decision-making cognition in a case of frontotemporal lobar degeneration (FTLD) presenting with pathologic gambling and hoarding as the initial symptoms. Cogn Behav Neurol 20: 121–125.
National Collaborating Center for Mental Health (2006). NICE Clinical Guidance CG31: Core Interventions in the Treatment of Obsessive Compulsive Disorder and Body Dysmorphic Disorder. London: British Psychiatric Society and Royal College of Psychiatrists.
Neacsiu AD, Rizvi SL, Linehan MM (2010). Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behav Res Ther 48: 832–839.
Nechmad A, Ratzoni G, Poyurovsky M, et al. (2003). Obsessive-compulsive disorder in adolescent schizophrenia patients. Am J Psychiatry 160: 1002–1004.
Nelson G, Janzen R, Trainor J, Ochocka J (2008). Putting values into practice: public policy and the future of mental health consumer-run organizations. Am J Community Psychol 42: 192–201.
Nestadt G, Samuels J, Riddle M, et al. (2001). The relationship between obsessive-compulsive disorder and anxiety and affective disorders: Results from the Johns Hopkins OCD Family Study. Psychol Med 31: 481–487.
Nestadt G, Samuels J, Riddle MA, et al. (2001). The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study. Psychol Med 31: 481–487.
Neziroglu F (1996). Effect of cognitive behavior therapy on persons with body dysmorphic disorder and comorbid axis II disorders. Behav Ther 27: 67–77.
Neziroglu F, Bubrick J, Yaryura-Tobias JA (2004). Overcoming Compulsive Hoarding. Oakland, CA: New Harbinger Press.
Neziroglu F, Henricksen J, Yaryura-Tobias J (2006). Psychotherapy of Obsessive-Compulsive Disorder and Spectrum: Established Facts and Advances 1995–5005. Psychiatr Clin N Am 29: 585–604.
Neziroglu F, Khemlani-Patel S (2002). A review of cognitive and behavioral treatment for body dysmorphic disorder. CNS Spectr 7: 464–471.
Neziroglu F, Khemlani-Patel S (2005). Overlap of body dysmorphic disorder and hypochondriasis with OCD. In Abramowitz JS, Houts AC (eds.) Concepts and Controversies in Obsessive-Compulsive Disorder (pp. 163–175). New York: Springer.
Neziroglu F, McKay D, Yaryura-Tobias J (2000). Overlapping and distinctive features of hypochondriasis and obsessive-compulsive disorder. J Anxiety Disord 14: 603–614.
Neziroglu F, McKay D, Yaryura-Tobias JA, Stevens K, Todaro J, (1999). The overvalues ideas scale: development, reliability and validity in obsessive-compulsive disorder. J Res Behav Ther 37: 881–902.
Neziroglu F, Neuman J (1990). Three approaches to the treatment of obsessions. Int J Cogn Ther 4: 371–392.
Neziroglu F, Steele J, Yaryura-Tobias JA (1990). Effect of behavior therapy on serotonin level in obsessive compulsive disorder. In Stefanis CN (ed.) Psychiatry: A World Perspective (pp. 707–710). New York: Elsevier.
Neziroglu F, Stevens K, McKay D, Yaryura-Tobias JA, (2001) Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders. J Res Behav Ther 39: 745–756.
Neziroglu F, Weissman S, Yaryura-Tobias JA, Allen J (2010). Compulsive hoarders: how they are similar to individuals with obsessive compulsive disorder? J Behav Res Ther in press.
Neziroglu F, Yaryura-Tobias JA (1993). Exposure, response prevention, and cognitive therapy in the treatment of body dysmorphic disorder. Behav Ther 24, 431–438.
Neziroglu F, Yaryura-Tobias JA (1993). Exposure, response prevention, and cognitive therapy in the treatment of body dysmorphic disorder. Behav Ther 24: 431–438.
Nicolson R, Lenane M, Hamburger SD, et al. (2000). Lessons from childhood-onset schizophrenia. Brain Res Brain Res Rev 31: 147–156.
Niehaus DJ, Koen L, Muller J, et al. (2005). Obsessive compulsive disorder: prevalence in Xhosa-speaking schizophrenia patients. S Afr Med J 95: 120–122.
Nierenberg AA, Phillips KA, Petersen TJ, et al. (2002). Body dysmorphic disorder in outpatients with major depression. J Affect Disord 69: 141–148.
Ninan PT, Koran LM, Kiev A, et al. (2006). High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67: 15–22.
Ninan PT, Rothbaum BO, Marsteller FA, Knight BT, Eccard MB (2000). A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry 61: 47–50.
Nordahl TE, Benkelfat C, Semple W, et al. (1989). Cerebral glucose metabolic rates in obsessive-compulsive disorder. Neuropsychopharmacology 2: 23–28.
Nordt C, Rossler W, Lauber C (2006). Attitudes of mental health professionals toward people tihe schizophrenia and major depression. Schizopr Bull 32: 709–714.
Nurnberg HG, Hensley PL, Gelenberg AJ, et al. (2003). Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 289: 56–64.
Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B (1999). Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 354: 1526.
O'Kearney RT, Anstey KJ, von Sanden C (2006). Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev (4):CD004856.
O'Sullivan G, Noshirvani H, Marks I, et al. (1991). Six year follow up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry 52: 150–155.
O'Sullivan RL, Keuthen NJ, Hayday CF, et al. (1995). The Massachusetts General Hospital (MGH) Hairpulling Scale: 2. reliability and validity. Psychother Psychosom 64: 146–148.
O'Sullivan RL, Phillips KA, Keuthen NJ, et al. (1999). Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics 40: 79–81.
O'Sullivan RL, Rauch SL, Breiter HC, et al. (1997). Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol Psychiatry 42: 39–45.
Obsessive Compulsive Cognitions Working Group (1997). Cognitive assessment of obsessive compulsive disorder. Behav Res Ther 35: 667–681.
Obsessive Compulsive Cognitions Working Group (1997). Cognitive assessment of obsessive-compulsive disorder. Behav Res Ther 35: 667–681.
OCD Ireland www.ocdireland.org/
OCD Organizations and Support Groups http://www.geonius.com/ocd/organizations.html
Ohta M, Kokai M, Morita Y (2003). Features of obsessive-compulsive disorder in patients primarily diagnosed with schizophrenia. Psychiatry Clin Neurosci 57: 67–74.
Okun MS, Bowers D, Springer U, et al. (2004). What's in a “smile?” Intra-operative observations of contralateral smiles induced by deep brain stimulation. Neurocase 10: 271–279.
Olatunji BO, Abramowitz JS, Williams NL, Connoly KM, Lohr JM (2007). Scrupulosity and obsessive-compulsive symptoms: confirmatory factor analysis and validity of the Penn Inventory of Scrupulosity. J Anxiety Disord 21: 771–787.
Olatunji BO, Lohr JM, Sawchuk CN, Tolin DF (2007). Multimodal assessment of disgust in contamination-related obsessive-compulsive disorder. Behav Res Ther 45: 263–276.
Olatunji BO, Sawchuk CN, Lohr JM, de Jong PJ (2004). Disgust domains in the prediction of contamination fear. Behav Res Ther 42: 93–104.
Ongür D, Goff DC (2005). Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 75: 349–362.
Orloff LM, Battle MA, Baer L, et al. (1994). Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 51: 441–442.
Otto MW, Wilhelm S, Cohen LS, et al. (2001). Prevalence of body dysmorphic disorder in a community sample of women. Am J Psychiatry 158: 2061–2063.
Pae CU, Patkar AA (2007). Paroxetine: current status in psychiatry. Expert Rev Neurother 7: 107–120.
Pallanti S, Hollander E (2008). Obsessive compulsive disorder spectrum as a scientific “metaphor”. CNS Spectr 13(Suppl 14): 6–15.
Pallanti S, Quercioli L (2006). Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 30: 400–412.
Pallanti S, Quercioli L, Bruscoli M (2004). Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65: 1394–1399.
Pallanti S, Quercioli L, Hollander E (2004). Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 161: 53–58.
Pallanti S, Quercioli L, Koran LM (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63: 796–801.
Pallanti S, Quercioli L, Paiva RS, Koran LM (1999).Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14: 101–106.
Pampaloni I, Sivakumaran T, Hawley C, et al. (2009). High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol 2009 (epub ahead of print; doi:10.1177/0269881109104850).
Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L (2005). Late cyst formation following gamma knife surgery of arteriovenous malformations. J Neurosurg 2005 102(Suppl): 124–127.
Pasquini M, Biondi M (2006). Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30: 1173–1175.
Pathak S, Danielyan A, Kowatch RA (2004). Successful treatment of trichotillomania with olanzapine augmentation in an adolescent. J Child Adolesc Psychopharmacol 14: 153–154.
Pauls D (2008). The genetics of obsessive-compulsive disorder: a review of the evidence. Am J Med Genet 148C: 133–139.
Pauls DL (2008). The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C: Semin Med Genet 148: 133–139.
Peasley-Miklus C, Massie E, Baslett G, Carmin C (2005). Treating obsessive-compulsive disorder and schizophrenia: The case of Sam. Cogn Behav Pract 12: 379–383.
Pediatric OCD Treatment Study Team (2004). Cognitive–behavioral therapy, sertraline, and their combination for children and adolescents with obsessive–compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292: 1969−1976.
Pediatric OCD Treatment Study Team (2004). Cognitive–behavioral therapy, sertraline, and their combination for children and adolescents with obsessive–compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292: 1969−1976.
Pediatric OCD Treatment Study Team (2004). Cognitive-behavioral therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study Randomized Controlled Trial. JAMA 292: 1969–1976.
Perani D, Colombo C, Bressi S, et al. (1995). FDG PET study in obsessive-compulsive disorder: a clinical metabolic correlation study after treatment. Br J Psychiatry 166: 244–250.
Perani D, Garibotto V, Gorini A, et al. (2008). In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 42: 306–314.
Perugi G, Akiskal H, Pfanner C, et al. (1997). The clinical impact of bipolar disorder and unipolar affective comorbidity on obsessive-compulsive disorder. J Affect Disord 46: 15–23.
Perugi G, Akiskal HS, Giannotti D, et al. (1997b). Gender-related differences in body dysmorphic disorder (dysmorphophobia). J Nerv Ment Dis 185: 578–582.
Perugi G, Akiskal HS, Lattanzi L, et al. (1998). The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry 39: 63–71.
Perugi G, Giannotti D, Di Vaio S, et al. (1996). Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 11: 247–254.
Perugi G, Giannotti D, Frare F, et al. (1997). Prevalence, phenomenology and co-morbidity of body dysmorphic disorder in a clinical population. Int J Psychiatr Clin Pract 1: 77–82.
Perugi G, Giannotti D, Frare F, et al. (1997a). Prevalence, phenomenology and comorbidity of body dysmorphic disorder (dysmorphophobia) in a clinical population. Int J Psych Clin Pract 1: 77–82.
Phelan JC, Bromet EJ, Link BG (1998). Psychiatric illness and family stigma. Schizophr Bull 24: 115–126.
Phelan JC, Link BG (1998). The growing belief that people with mental illnesses are violent: the role of the dangerousness criterion for civil commitment. Social Psychiatry Psychiatr Epidemiol 33(Suppl 1): S7–S12.
Phillips KA (1991). Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry 148: 1138–1149.
Phillips KA (2000). Quality of life for patients with body dysmorphic disorder. J Nerv Ment Dis 188: 170–175.
Phillips KA (2004). Psychosis in body dysmorphic disorder. J Psychiatr Res 38: 63–72.
Phillips KA (2005a). The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder, revised edn. New York: Oxford University Press.
Phillips KA (2005b). Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 162: 377–379.
Phillips KA (2005c). Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 162: 1022–1023.
Phillips KA (2006). An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 21: 177–179.
Phillips KA (2009). Understanding Body Dysmorphic Disorder: An Essential Guide. New York: Oxford University Press.
Phillips KA, Albertini RS, Rasmussen SA (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59: 381–388.
Phillips KA, Albertini RS, Siniscalchi JM, et al. (2001b). Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 62: 721–727.
Phillips KA, Coles ME, Menard W, et al. (2005c). Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry 66: 717–725.
Phillips KA, Conroy M, Dufresne RG, et al. (2006b). Tanning in body dysmorphic disorder. Psychiatr Q 77: 129–138.
Phillips KA, Diaz SF (1997). Gender differences in body dysmorphic disorder. J Nerv Ment Dis 185: 570–577.
Phillips KA, Didie ER, Menard W (2007). Clinical features and correlates of major depressive disorder in individuals with body dysmorphic disorder. J Affect Disord 97: 129–135.
Phillips KA, Didie ER, Menard W, et al. (2006c). Clinical features of body dysmorphic disorder in adolescents and adults. Psychiatry Res 141: 305–314.
Phillips KA, Dwight MM, McElroy SL (1998a). Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 59: 165–171.
Phillips KA, Grant J, Siniscalchi J, et al. (2001a). Surgical and non-psychiatric medical treatment of patients with body dysmorphic disorder. Psychosomatics 42: 504–510.
Phillips KA, Gunderson CG, Mallya G, et al. (1998b). A comparison study of body dysmorphic disorder and obsessive-compulsive disorder. J Clin Psychiatry 59: 568–575.
Phillips KA, Hollander (2008). Treating body dysmorphic disorder with medication: evidence, misconceptions and a suggested approach. Body Image 5: 13–27.
Phillips KA, Kaye WH (2007). The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. CNS Spectr 12: 347–358.
Phillips KA, McElroy SL (2000). Personality disorders and traits in patients with body dysmorphic disorder. Compr Psychiatry 41: 229–236.
Phillips KA, McElroy SL, Keck PE, Jr., et al. (1993). Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 150: 302–308.
Phillips KA, McElroy SL, Keck PE, Jr., et al. (1994). A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull 30: 179–186.
Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI (1993). Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 150: 302–308.
Phillips KA, McElroy SL, Lion JR (1992). Body dysmorphic disorder in cosmetic surgery patients. J Plast Reconst Surg 90: 333–334.
Phillips KA, Menard W (2006). Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry 163: 1280–1282.
Phillips KA, Menard W, Fay C, et al. (2005a). Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics 46: 317–25.
Phillips KA, Menard W, Fay C, et al. (2005b). Psychosocial functioning and quality of life in body dysmorphic disorder. Compr Psychiatry 46: 254–260.
Phillips KA, Menard W, Fay C, et al. (2006a). Gender similarities and differences in 200 individuals with body dysmorphic disorder. Compr Psychiatry 47: 77–87.
Phillips KA, Najjar F (2003). An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 64: 715–720.
Phillips KA, Nierenberg AA, Brendel G, et al. (1996). Prevalence and clinical features of body dysmorphic disorder in atypical major depression. J Nerv Ment Dis 184: 125–129.
Phillips KA, Pagano ME, Menard W (2006d). Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity. Ann Clin Psychiatry 18: 251–257.
Phillips KA, Pagano ME, Menard W, et al. (2005d). Predictors of remission from body dysmorphic disorder: a prospective study. J Nerv Ment Dis 193: 564–567.
Phillips KA, Pinto A, Jain S (2004a). Self-esteem in body dysmorphic disorder. Body Image 1: 385–390.
Phillips KA, Pinto A, Menard W, et al. (2006e). Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders. Depress Anxiety 24: 399–409.
Phillips KA, Siniscalchi JM, McElroy SL (2004b). Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q 75: 309–320.
Phillips KA, Stout RL (2006). Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive compulsive disorder, and social phobia. J Psychiatr Res 40: 360–369.
Phillips KA, Taub SL (1995). Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull 31: 279–288.
Phillips M, Marks I, Senior C, et al. (2000). A differential neural response in obsessive-compulsive disorder patients with washing compared with checking symptoms to disgust. Psychol Med 30: 1037–1050.
Physicians Desk Reference (2006). Montvale NJ: PDR Network, Thomson http://www.pdr.net/login/Login.aspx (accessed 26 July 2010).
Piacentini J, Bergman RL (2000). Obsessive-compulsive disorder in children. Psychiatr Clin N Am 23: 519–533.
Piacentini J, Bergman RL, Jacobs C, McCracken JT, Kretchman J (2002). Open trial of cognitive behavior therapy for childhood obsessive-compulsive disorder. J Anxiety Disord 16: 207–219.
Piacentini J, Gitow A, Jaffer M, Graae F, Whitaker A (1994). Outpatient behavioral treatment of child and adolescent obsessive-compulsive disorder. J Anxiety Disord 8: 277–289.
Piacentini J, Gitow A, Jaffer M, Graae F, Whitaker A (1994). Outpatient behavioral treatment of child and adolescent obsessive-compulsive disorder. J Anxiety Disord 8: 277–289.
Piacentini J, Jaffer M, Bergman RL, McCracken J, Keller M (2001). Measuring impairment in childhood OCD: Psychometric properties of the COIS. Sci Proc Am Acad Child Adolesc Psychiatry 48: 146.
Piccinelli M, Pini S, Bellantouono C, et al. (1995). Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 166: 424–443.
Pierre JM, Guze BH (2000). Benztropine for venlafaxine-induced night sweats. J Clin Psychopharmacol 20: 269.
Pigott TA, L'Heureux F, Hill JL, et al. (1992a). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11–18.
Pigott TA, L'Heureux F, Rubenstein CS, et al. (1992b). A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 156–162.
Pigott TA, Pato MT, Bernstein SE, et al. (1990). Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 47: 926–932.
Pine DS (2002). Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 12: 189–203.
Pinto A, Eisen JL, Mancebo M, et al. (2007). A 2-year follow-up study of the course of obsessive-compulsive disorder. In Proceeding of the the Association of Behavioral and Cognitive Therapies, Philadelphia, November.
Pinto A, Francis G (1993). Obsessive-compulsive disorder in children. In Hersen M, Ammerman RT (eds.) Handbook of Behavioral Therapy with Children andAdults: A Longitudinal Perspective (pp. 155–165). New York: Allyn & Bacon.
Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA (2006). The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 67: 703–711.
Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA (2006). The Brown Longitudinal Obsessive-Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 67: 703–711.
Pinto A, Phillips KA (2005). Social anxiety in body dysmorphic disorder. Body Image 2: 401–405.
Pistrang N, Barker C, Humphreys K (2008). Mutual help groups for mental health problems: a review of effectiveness studies. Am J Community Psychol 42: 110–121.
Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008). Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 28: 363–367.
Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 3: 69–81.
Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 3: 69–81.
Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 3: 69–81.
Pittenger C, Krystal JH, Coric V (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutivs 3: 69–81.
Plewnia C, Schober F, Rilk A, et al. (2008). Sustained improvement of obsessive-compulsive disorder by deep brain stimulation in a woman with residual schizophrenia. Int J Neuropsychopharmacol 13: 1–3.
Pollock RA, Carter AS (1999). The familial and developmental context of obsessive-compulsive disorder. Child Adolesc Psychiatr Clin N Am 8: 461–479.
Pool JL (1954). Psychosurgery in older people. J Am Geriat Soc 7: 456–466.
Pope CG, Pope HG, Menard W, et al. (2005). Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body Image 2: 395–400.
Porto L, Bermanzohn PC, Pollack S (1997). A profile of obsessive-compulsive symptoms in schizophrenia. CNS Spectr 2: 21–25.
Postemak M, Zimmerman M (2005). Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors. J Clin Psychiatry 66: 705–707.
Potenza MN, Wasylink S, Epperson CN, McDougle CJ (1998). Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 155: 1299–1300.
Poyurovsky M, Bergman J, Weizman R (2006b). Obsessive-compulsive disorder in elderly schizophrenia patients. J Psychiatry Res 40: 189–191.
Poyurovsky M, Dorfman-Etrog P, Hermesh H, et al. (2000). Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol 15: 169–173.
Poyurovsky M, Faragian S, Kleinman-Balush V, et al. (2007). Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder. J Nerv Ment Dis 195: 765–768.
Poyurovsky M, Faragian S, Pashinian A, et al. (2008b). Clinical characteristics of schizotypal-related obsessive-compulsive disorder. Psychiatry Res 159: 254–258.
Poyurovsky M, Faragian S, Shabeta A, Kosov A (2008a). Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder. Psychiatry Res 159: 133–139.
Poyurovsky M, Fuchs C, Faragian S, et al. (2006a). Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry 51: 746–754.
Poyurovsky M, Fuchs K, Weizman A (1999a). Obsessive-compulsive symptoms in patients with first episode schizophrenia. Am J Psychiatry 156: 1998–2000.
Poyurovsky M, Glick I, Koran LM (2010). Lamotrigine augmentation in schizoprhenia and schizo-affective patients with obsessive-compulsive symptoms. J Psychopharmacol 24: 861–866.
Poyurovsky M, Hromnikov S, Isakov V, et al. (2001). Obsessive-compulsive disorder in chronic institutionalized schizophrenic patients. Psychiatry Res 102: 49–57.
Poyurovsky M, Isakov V, Hromnikov S, et al. (1999b). Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14: 95–100.
Poyurovsky M, Kriss V, Weisman G, et al. (2003). Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. J Clin Psychiatry 64: 1300–1307.
Poyurovsky M, Weizman A (1998). Intravenous clomipramine for a schizophrenic patient with obsessive-compulsive symptoms. Am J Psychiatry 155: 1993.
Poyurovsky M, Weizman A, Weizman R, (2004). Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 18: 989–1010.
Poyurovsky M, Weizman R, Weizman A, Koran L (2005). Memantine for treatment-resistant OCD. Am J Psychiatry 162: 2191–2192.
Pressman JD (1998) Last Resort: Psychosurgery and the Limits of Medicine. Cambridge, UK: Cambridge University Press.
Price BH, Baral I, Cosgrove GR, et al. (2001). Improvement in severe self-mutilation following limbic leucotomy: a series of 5 consecutive cases. J Clin Psychiatry 62: 925–932.
Prince JD, Akincigil A, Kalay E, et al. (2008). Psychiatric rehospitalization among elderly persons in the United States. Psychiatr Serv 59: 1038–1045.
Purcell J (1999). Children, adolescents and obsessive-compulsive disorder in the classroom. ERDS Guides 1–22.
Rabavilas AD, Boulougouris JC, Stefanis D (1976). Duration of flooding session in the treatment of obsessive compulsive patients. Behav Res Ther 14: 349–355.
Rachman S (1993). Obsessions, responsibilities, and guilt. Behav Res Ther 31: 149–154.
Rachman S (1993). Obsessions, responsibility, and guilt. Behav Res Ther 31: 149–154.
Rachman S (1997). A cognitive theory of obsessions. Behav Res Ther 36: 385–401.
Rachman S (1998). A cognitive theory of obsessions: elaborations. Behav Res Ther 35: 793–802.
Rachman S, Hodgson R, Marks IM (1971). The treatment of chronic obsessive-compulsive neurosis. Behav Res Ther 9: 237–247.
Rachman S, Marks I, Hodgson R (1973). The treatment of obsessive-compulsive neurotics by modeling and flooding in vivo. Behav Res Ther 11: 463–471.
Rachman SJ, Hodgson RJ (1980). Obsessions and Compulsions (pp. 57–68). Englewood Cliffs, NJ: Prentice-Hall.
Rack M, Chir D (1970). Experience with intravenous clomipramine. In Salzman L (ed.) Obsessional States and their Treatment with Anafranil (pp. 10–13). Macclesfield, UK: Geigy.
Rajkumar RP, Reddy YC, Kandavel T (2008). Clinical profile of “schizo-obsessive” disorder: a comparative study. Compr Psychiatry 49: 262–268.
Ramasubbu R (2002). Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Arch Gen Psychiatry 59: 472; author reply 472–473.
Rapaport MH, Clary C, Faayed R, et al. (2005). Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 162: 1171–1178.
Rapoport J, Inoff-Germain G, Weissman M, et al. (2000). Childhood obsessive-compulsive disorder in the NIMH MECA study. Parent vs. child identification of cases. J Anxiety Disord 14: 535–548.
Rasmussen BB, Maenpaa J, Pelkonen O, et al. (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151–159.
Rasmussen J, Steketee G, Frost RO, Tolin DF (2007). Prevalence and associated characteristics of squalor in an internet sample of compulsive hoarders. In Proceeding of the the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia, November.
Rasmussen S, Hackett E, DuBoff E, et al. (1997). A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12: 309–316.
Rasmussen SA, Eisen JL (1989). Clinical features and phenomenology of obsessive compulsive disorder. Psychiatr Ann 19: 67–73.
Rasmussen SA, Eisen JL (1990). Epidemiology of obsessive compulsive disorder. J Clin Psychiatry 51(Suppl): 10–13.
Rasmussen SA, Eisen JL (1992). The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin N Am 15: 743–758.
Rasmussen SA, Eisen JL (1992). The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin N Am 15: 743–758.
Rasmussen SA, Eisen JL (1992). The epidemiology and clinical features of obsessive-compulsive disorder. J Clin Psychiatry 53: 4–10.
Rasmussen SA, Eisen JL (1994). Epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 55(Suppl): 5–14.
Rasmussen SA, Tsuang MT (1986). Clinical characteristics and family history in DSM-III obsessive compulsive disorder. Am J Psychiatry 14: 317–322.
Rasmussen SA, Tsuang MT (1986). Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 143: 317–322.
Rasmussen SA, Tsuang MT (1986). Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 143: 317–322.
Rauch SL, Baer L, Jenike MA (1996). Treatment resistant obsessive-compulsive disorder: practical strategies for management. In Pollack MH, Otto MW, Rosenbaum JF (eds.) Challenges in Psychiatric Treatment: Pharmacologic and Psychosocial Perspectives (pp. 201–218). New York: Guilford Press.
Rauch SL, Dougherty DD, Cosgrove GR, et al. (2001). Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry 50: 659–667.
Rauch SL, Jenike MA, Alpert NM, et al. (1994). Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using 15O-labeled CO2 and positron emission tomography. Arch Gen Psychiatry 51: 62–70.
Rauch SL, Jenike MA, Alpert NM, et al. (1994). Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51: 62–70.
Rauch SL, Phillips KA, Segal E, et al. (2003). A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder. Psychiatry Res 122: 13–19.
Rauch SL, Savage CR, Alpert NM, et al. (1997). Probing striatal function in obsessive-compulsive disorder: a PET study of implicit sequence learning. J Neuropsychiatry Clin Neurosci 9: 568–573.
Rauch SL, Shin LM, Dougherty DD, et al. (2002). Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27: 782–791.
Rauch SL, Wright CI, Savage CR, et al. (2007). Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiatry Res 154: 233–240.
Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995). Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 56: 368–373.
Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996). Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 32: 677–682.
Rector NA, Richter MA, Bagby RM (2005). The impact of personality on symptom expression in obsessive compulsive disorder. J Nerv Ment Dis 193: 231–236.
Regier DA, Narrow WE, Rae DS (1990). The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. J Psychiatry Res 24(Suppl 2): 3–14.
Reid S, Barbui C (2010). Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 340: c1468.
Reinblatt SP, Riddle MA (2006). Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series. J Child Adolesc Psychopharmacol 16: 227–233.
Renshaw KD, Chambless DL, Rodebaugh TL, Steketee G (2000). Living with severe anxietydisorders: relatives' distress and reactions to patient behaviours. Clin Psychol Psychother 7: 190–200.
Renshaw KD, Chambless DL, Steketee G (2003). Perceived criticism predicts severity of anxiety symptoms after behavioral treatment in patients with obsessive-compulsive disorder and panic disorder with agoraphobia. J Clin Psychol 59: 411–421.
Reznik I, Sirota P (2000). Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20: 410–416.
Ricciardi JN, McNally RJ (1995). Depressed mood is related to obsessions but not compulsions in obsessive-compulsive disorder. J Anxiety Disord 9: 249–256.
Riddle M (1998). Obsessive-compulsive disorder in children and adolescents. Br J Psychiatry 173: 91–96.
Riddle MA, Hardin MT, King R, Scahill L, Woolston JL (1990). Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29: 45–48.
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40: 222–229.
Riddle MA, Scahill L, King RA, et al. (1992). Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31: 1062–1069.
Rief W, Buhlmann U, Wilhelm S, et al. (2006). The prevalence of body dysmorphic disorder: a population-based survey. Psychol Med 36: 877–885.
Roberts LJ, Salem D, Rappaport J, et al. (1999). Giving and receiving help: interpersonal transactions in mutual self help meetings and psychosocial adjustment of members. Am J Community Psychol 27: 841–868.
Robinson D, Wu H, Munne RA, et al. (1995) Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry 52: 393–398.
Rodrigues Torres A, Del Porto JA (1995). Comorbidity of obsessive-compulsive disorder and personality disorders. a Brazilian controlled study. Psychopathology 28: 322–329.
Rolls ET (2004). The functions of the orbitofrontal cortex. Brain Cogn 55: 11–29.
Romano S, Goodman W, Tamura R, Gonzales J (2001). Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 21: 46–52.
Rosario-Campos MC, Miguel EC, Quatrano S, et al. (2006). The Dimensional Yale–Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry 11: 495–504.
Rosen I (1956). The clinical significance of obsessions in schizophrenia. J Mental Sci 103: 773–785.
Rosen JC, Ramirez E (1998). A comparison of eating disorders and body dysmorphic disorder on body image and psychological adjustment. J Psychosom Res 44: 441–449.
Rosen JC, Reiter J, Orosan P (1995). Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol 63: 263–269.
Rosen RC, Lane RM, Menza M (1999). Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19: 67–85.
Rosenberg DR, MacMaster FP, Keshavan MS, et al. (2000). Decrease in caudate glutamatergic concentrations in pediatric obsessive- compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39: 1096–1103.
Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E (1999). Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 38: 1180–1185.
Ross RG, Heinlein S, Tregellas H (2006). High rates of comorbidity are found in childhood-onset schizophrenia. Schizophr Res 88: 90–95.
Rossi A, Daneluzzo E (2002). Schizotypal dimensions in normals and schizophrenic patients: a comparison with other clinical samples. Schizophr Res 54: 67–75.
Rubin RT, Villaneuva-Myer J, Ananth J, et al. (1992). Regional xenon-133 cerebral blood flow and cerebral technetium-99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Arch Gen Psychiatry 49: 695–702.
Ruck C, Karlsson A, Steele JD, et al. (2008). Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients. Arch Gen Psychiatry 65: 914–921.
Rufer M, Hand I, Alsleben H, et al. (2005). Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 255: 121–128.
Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15: 53–63.
Rutz W (2006). Social psychiatry and the public mental health: present situation and future objectives; Time for rethinking and renaissance? Acta Psychiatr Scand 113: 95–100.
Salkovskis P, Shafran R, Rachman S, Freeston MH (1999). Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research. Behav Res Ther 37: 1055–1072.
Salkovskis PM (1985). Obsessional compulsive problems: a cognitive behavioral analysis. Behav Res Ther 23: 571–583.
Salkovskis PM (1998). Cognitive behavioral approach to understanding obsessional thinking. Br J Psychiatry 173(Suppl 35): 53–63.
Salkovskis PM, Richards CH, Forrester E (1995). The relationship between obsessional problems and intrusive thoughts. Behav Cogn Psychother 23: 281–299.
Salkovskis PM, Warwick HM (1985). Cognitive therapy of obsessive-compulsive disorder: treating treatment failures. Behav Psychother 13: 243–255.